<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Endocrinol Invest</journal-id><journal-id journal-id-type="iso-abbrev">J Endocrinol Invest</journal-id><journal-title-group><journal-title>Journal of Endocrinological Investigation</journal-title></journal-title-group><issn pub-type="ppub">0391-4097</issn><issn pub-type="epub">1720-8386</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39347908</article-id><article-id pub-id-type="pmc">PMC11785607</article-id>
<article-id pub-id-type="publisher-id">2430</article-id><article-id pub-id-type="doi">10.1007/s40618-024-02430-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Interleukin-5: an indicator of mild cognitive impairment in patients with type 2 diabetes mellitus - a comprehensive investigation ranging from bioinformatics analysis to clinical research</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhu</surname><given-names>Wenwen</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Yang</surname><given-names>Shufang</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Niu</surname><given-names>Tong</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fareeduddin Mohammed Farooqui</surname><given-names>Huzaifa</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Bing</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Hongxiao</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Sumei</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jumei</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Linlin</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Zhen</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6937-4252</contrib-id><name><surname>Zhang</surname><given-names>Haoqiang</given-names></name><address><email>drhqzhang@ustc.edu.cn</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05d80kz58</institution-id><institution-id institution-id-type="GRID">grid.453074.1</institution-id><institution-id institution-id-type="ISNI">0000 0000 9797 0900</institution-id><institution>Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, College of Clinical Medicine of Henan, </institution><institution>University of Science and Technology, </institution></institution-wrap>Luoyang, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01k3hq685</institution-id><institution-id institution-id-type="GRID">grid.452290.8</institution-id><institution>Department of Endocrinology, </institution><institution>Affiliated Zhongda Hospital of Southeast University, </institution></institution-wrap>Nanjing, China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02fvevm64</institution-id><institution-id institution-id-type="GRID">grid.479690.5</institution-id><institution>Department of Endocrinology, </institution><institution>Taizhou People&#x02019;s Hospital, </institution></institution-wrap>Taizhou, China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00yx0s761</institution-id><institution-id institution-id-type="GRID">grid.452867.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 5903 9161</institution-id><institution>Department of Endocrinology, </institution><institution>The First Affiliated Hospital of Jinzhou Medical University, </institution></institution-wrap>Jinzhou, China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04c4dkn09</institution-id><institution-id institution-id-type="GRID">grid.59053.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2167 9639</institution-id><institution>Department of Endocrinology, Institute of Endocrine and Metabolic Diseases, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, </institution><institution>University of Science and Technology of China, </institution></institution-wrap>Hefei, 230001 China </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>30</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>48</volume><issue>2</issue><fpage>401</fpage><lpage>417</lpage><history><date date-type="received"><day>27</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>12</day><month>7</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">Neuroinflammation constitutes an underlying mechanism for cognitive impairment. Here, we endeavor to scrutinize the potential contribution of interleukin-5 (IL-5) towards mild cognitive impairment (MCI), and to assess its diagnostic value for MCI in patients with type 2 diabetes mellitus (T2DM).</p></sec><sec><title>Methods</title><p id="Par2">RNA-seq was used to explore the potential neuroinflammation factors in the hippocampus of diabetic mice with cognitive decline. Additionally, the promising risk factor was verified in animals. Finally, the association between IL-5 levels and cognitive function and its diagnostic value for MCI were assessed.</p></sec><sec><title>Results</title><p id="Par3">In animals, up-regulated IL-5 mRNA and protein levels were detected by RNA-seq and (or) verified experiments in the hippocampus of diabetic db/db mice with cognitive decline, compared to those of db/m mice without diabetes. In human, compared to diabetic patients without MCI, those with MCI demonstrate elevated levels of IL-5. It is natively associated with Montreal Cognitive Assessment (MoCA) scores, reflecting global cognitive function, and positively correlated with Trail Making Test A (TMTA) scores, reflecting information processing speed. Furthermore, an elevated level of IL-5 is identified as a risk factor for MCI, and a factor that influences TMTA scores. Finally, it is recommended that the cut-off value for IL-5 in the diagnosis of MCI is 22.98 pg/mL, with a sensitivity of 68.6% and specificity of 72.9%.</p></sec><sec><title>Conclusions</title><p id="Par4">IL-5 is considered a risk factor for MCI in T2DM patients and is associated with their performance in information processing speed. Moreover, an elevated level of IL-5 is a plausible biomarker for MCI in T2DM patients.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Type 2 diabetes mellitus</kwd><kwd>Mild cognitive impairment</kwd><kwd>Neuroinflammation</kwd><kwd>Interleukin-5</kwd></kwd-group><funding-group><award-group><funding-source><institution>Scientific Research Start-up Funds of The First Affiliated Hospital of USTC</institution></funding-source><award-id>RC2021178</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Haoqiang</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Research Funds of Center for Leading Medicine and Advanced Technologies of IHM</institution></funding-source><award-id>2023IHM02006</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Haoqiang</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>China Endocrine Metabolism Talent Research Project from China International Medical Foundation</institution></funding-source><award-id>2023-N-03-12</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Haoqiang</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Italian Society of Endocrinology (SIE) 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par10">In 2021, a total of 537&#x000a0;million individuals across the globe were diagnosed with diabetes. According to estimates, this number is expected to increase to 643&#x000a0;million and 783&#x000a0;million by 2030 and 2045, respectively [<xref ref-type="bibr" rid="CR1">1</xref>]. Among the various types of diabetes, T2DM is the most prevalent, and is characterized by persistent hyperglycemia, insulin resistance, oxidative stressand chronic inflammation [<xref ref-type="bibr" rid="CR2">2</xref>], which are associated with a range of diabetic complications, including neuronal dysfunctions [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. MCI represents an intermediary stage between normal cognition and dementia [<xref ref-type="bibr" rid="CR9">9</xref>], and its early identification and management could potentially prevent disease progression and even restore normal cognitive function [<xref ref-type="bibr" rid="CR10">10</xref>]. Recently, our study demonstrated that elevated levels of inflammation factors are linked to MCI, particularly memory deficits, in patients with T2DM [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par11">Our recent studies suggest that cholesterol [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>] and fatty acid [<xref ref-type="bibr" rid="CR15">15</xref>] disorders are associated with cognitive impairment in patients with T2DM. IL-5 is a cytokine associated with inflammation and is released from group II innate lymphoid cells. It is closely related to allergic inflammation, parasitic infections, and even lipid metabolism [<xref ref-type="bibr" rid="CR16">16</xref>]. Indeed, IL-5 is also associated with cognitive function in both children [<xref ref-type="bibr" rid="CR17">17</xref>] and adults [<xref ref-type="bibr" rid="CR18">18</xref>], irrespective of diabetes status. Furthermore, studies suggest that IL-5 is associated with cognitive function in animals as well [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par12">Regarding T2DM, serum levels of IL-5 are significantly higher in patients with T2DM than in the control group [<xref ref-type="bibr" rid="CR21">21</xref>]. Patients with non-proliferative diabetic retinopathy and proliferative diabetic retinopathy exhibit elevated IL-5 levels compared to diabetic patients without retinopathy. Additionally, the concentration of IL-5 is higher in the proliferative diabetic retinopathy group than in the non-proliferative diabetic retinopathy group [<xref ref-type="bibr" rid="CR22">22</xref>]. IL-5 mRNA levels are also increased in patients with diabetic nephropathy compared to those without diabetic nephropathy [<xref ref-type="bibr" rid="CR23">23</xref>]. These studies suggest that IL-5 may not only be related to the occurrence of diabetes but also to the development of diabetic complications. Our previous studies have suggested that levels of brain-derived neurotrophic factor in plasma are associated with memory prognosis in long-term T2DM patients [<xref ref-type="bibr" rid="CR24">24</xref>]. Interestingly, down-regulated levels of brain-derived neurotrophic factor were observed in functional dyspepsia patients, while elevated levels of IL-5 were detected in those patients [<xref ref-type="bibr" rid="CR25">25</xref>]. Additionally, IL-5 is a member of the Interleukin-3 (IL-3) family. Upon binding with its receptor, IL-5, along with other members of the IL-3 family, can potentially participate in neuronal apoptosis and subsequently influence cognitive function through the JAK/STAT signaling pathway. This may be one of the mechanisms of diabetic dysfunction [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. These findings suggest potential associations between diabetic cognitive impairment and IL-5 levels.</p><p id="Par13">Although IL-5 is both associated with cognitive dysfunction and diabetes (including diabetic complications), the relationship between IL-5 and MCI in T2DM patients is still unclear. Generally, there may be a potential correlation between IL-5 and MCI in patients with T2DM. However, the specific nature of this relationship requires further confirmation. Moreover, the connection between IL-5 and more intricate cognitive functions remains to be explored. Early detection of MCI can be beneficial, but its latent onset and mild symptoms present challenges in timely recognition. Presently, diagnosis of MCI relies on evaluation of relevant scales, which can be subjective and time-consuming. Furthermore, invasive examinations may be needed, and imaging studies can be prohibitively expensive. Consequently, there is an urgent need for minimally invasive diagnostic markers that are easy to perform. As such, IL-5 has the potential to serve as a biomarker that can be easily detected in peripheral blood. Thus, our study aims to investigate the association between MCI (including cognitive performance details) and IL-5 levels in patients with T2DM. Additionally, we evaluate the diagnosis cut-off point and diagnosis value by using the ROC curve.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Animal housing</title><p id="Par14">The investigation encompassed the utilization of 7-week-old male db/db mice (<italic>n</italic>&#x02009;=&#x02009;10) and db/m mice (<italic>n</italic>&#x02009;=&#x02009;10), obtained from Beijing HFK Biotechnology Co., Ltd. (Beijing, China), and subsequently housed in a specific pathogen-free animal facility. After a duration of 16 weeks, all experimental mice underwent anesthesia through the administration of 4% halothane, followed by humane euthanasia via cervical vertebra dislocation. Post-euthanasia, both blood and brain tissue specimens were expeditiously collected and preserved at -80&#x000a0;&#x000b0;C to facilitate subsequent research endeavors. It is noteworthy that the research was conducted in strict accordance with the principles delineated in the &#x0201c;Guide for the Care and Use of Laboratory Animals&#x0201d; and received ethical clearance from the Animal Studies Committee at our institution.</p></sec><sec id="Sec4"><title>Morris water maze</title><p id="Par15">The Morris water maze paradigm was employed for the assessment of cognitive function subsequent to the dietary interventions elucidated earlier, in adherence to established methodologies articulated in previous investigations [<xref ref-type="bibr" rid="CR31">31</xref>]. During the initial test session, mice underwent a one-minute period of unimpeded swimming to acclimate themselves to the environment, devoid of the presence of the concealed platform. Subsequent to this acclimatization phase, each mouse participated in a five-day training regimen within the maze, wherein a concealed platform was strategically positioned within the apparatus. Quantitative parameters, specifically the escape latency (defined as the time taken by each mouse to locate the concealed platform) and the path length traversed by each mouse, were systematically documented throughout the training period. On the sixth day of testing, supplementary performance metrics were recorded in the absence of the platform, encompassing the percentage of time spent in the target quadrant, the frequency of crossings over the platform area, and the swimming speed of the mice.</p></sec><sec id="Sec5"><title>mRNA library construction, sequencing and functional enrichment analysis</title><p id="Par16">The information for mRNA library construction and sequencing are shown in Supplementary File 1. All sequencing procedure were performed by Shenyang Jianji Biotechnology Co., Ltd.</p></sec><sec id="Sec6"><title>Real time polymerase chain reaction (RT-PCR)</title><p id="Par17">Total RNA was extracted using TRIzol reagent (Thermo Fisher, USA, Catalogue No.: 15,596,026). Subsequently, the isolated RNA underwent reverse transcription into cDNA employing HiScript III RT SuperMix (Vazyme, Nanjing, China, Catalogue No.: R223-01), following the manufacturer&#x02019;s provided protocols. Quantitative real-time PCR was conducted on the Applied Biosystems StepOnePlus system utilizing SYBR Green (Vazyme, Nanjing, China, Catalogue No.: Q341-02). The primer sequences employed were as follows: IL-5 forward primer, 5&#x02032;-ATGGAGATTCCCATGAGCAC-3&#x02032; and reverse primer, 5&#x02032;-GTCTCTCCTCGCCACACTTC-3&#x02032;; GAPDH forward primer, 5&#x02032;-CGGAGTCAACGGATTTGGTCGTAT-3&#x02032; and reverse primer, 5&#x02032;-AGCCTTCTCCATGGTGGTGAAGAC-3&#x02032;. The PCR cycling conditions comprised an initial denaturation step (95&#x000a0;&#x000b0;C for 2&#x000a0;min) followed by 40 cycles of denaturation (95&#x000a0;&#x000b0;C for 15s), annealing (55&#x000a0;&#x000b0;C for 30s), extension (72&#x000a0;&#x000b0;C for 30s), and acquisition temperature (15s). Gene expression analysis was conducted using the 2<sup>&#x02212;(&#x00394;Ct)</sup> method, normalizing to GAPDH as the reference gene.</p></sec><sec id="Sec7"><title>Western blotting (WB)</title><p id="Par18">The Western blotting procedure was conducted in accordance with a previously established protocol [<xref ref-type="bibr" rid="CR32">32</xref>] outlined as follows. Hippocampal tissue was isolated for protein extraction utilizing radioimmunoprecipitation (Wanlei Biotechnology Co. Ltd, Shenyang, China, Catalogue No.: WLA016a) and quantified using a BCA assay following the manufacturer&#x02019;s instructions (Wanlei Biotechnology Co. Ltd, Shenyang, China, Catalogue No.: WLA004b). Subsequently, proteins were resolved on SDS-PAGE gels and transferred onto polyvinylidene fluoride membranes. Primary antibodies, specifically rabbit anti-mouse antibodies, were employed to selectively bind target proteins such as IL-5 (Wanlei Biotechnology Co. Ltd, Shenyang, China, Catalogue No.: WLA 01401) and &#x003b2;-actin (Wanlei Biotechnology Co. Ltd, Shenyang, China, Catalogue No.: WLA01372) at 4&#x000a0;&#x000b0;C overnight. Following primary antibody binding, incubation with goat-anti-rabbit secondary antibodies conjugated with HRP (Wanlei Biotechnology Co. Ltd, Shenyang, China, Catalogue No.: WLA023a) was conducted. Detection of protein levels was accomplished through the utilization of an ECL kit (Wanlei Biotechnology Co. Ltd, Shenyang, China, Catalogue No.: WLA006a) prior to exposure.</p></sec><sec id="Sec8"><title>Immunofluorescence</title><p id="Par19">Fresh mouse brains were harvested and subjected to embedding in optimal cutting temperature compound (OTC) for the preparation of frozen Sect.&#x000a0;(40&#x000a0;&#x003bc;m) inclusive of the hippocampus. Prior to overnight incubation at 4&#x000a0;&#x000b0;C with rabbit anti-mouse primary antibody to IBA-1 (Huabio, Hangzhou, China, Catalogue No.: ET1705-78) and rat anti-mouse primary antibody CD68 (Bio-Rad, Oxford, UK, Catalogue No.: MCA1957T), all sections underwent blocking in phosphate-buffered saline (PBS) containing 5% normal goat serum for 1&#x000a0;h at room temperature. Following triple washes with PBS, detection of primary antibodies was achieved using FITC-conjugated goat anti-rabbit secondary antibody (Servicebio, Wuhan, China, Catalogue No.: GB22302) and Cy3-conjugated goat anti-rat secondary antibody (Servicebio, Wuhan, China, Catalogue No.: GDP1012) in a light-protected environment. Subsequent to three additional PBS washes, visualization of IBA-1 and CD68 was conducted utilizing a confocal microscope.</p></sec><sec id="Sec9"><title>Enzyme-linked immunosorbent assay (ELISA)</title><p id="Par20">In conjunction with the aforementioned measurements, blood samples were procured simultaneously and processed to obtain plasma. Specifically, collected blood samples were subjected to centrifugation at 4&#x000a0;&#x000b0;C for 30&#x000a0;min, with a relative centrifugal force of 1000&#x000a0;g. The resulting plasma samples were then subjected to quantification of IL-5 levels by the kit of enzyme-linked immunosorbent assay following the manufacturer&#x02019;s protocol for mouse (Cloud-Clone Corp., China, Wuhan, Catalogue No.: SEA078Mu) and human (Cloud-Clone Corp., China, Wuhan, Catalogue No.: SEA078Hu). Additionally, levels of TNF-&#x00251;, IL-6, IL-1&#x003b2;, and IL-10 were measured in the protein extraction solution from hippocampal tissue of mice by similar kits (Cloud-Clone Corp., China, Wuhan, Catalogue No.: MEA133Mu, SEA079Mu, SEA563Mu, and SEA056Mu).</p></sec><sec id="Sec10"><title>Clinical study design and clinical ethical approval</title><p id="Par21">A total of 105 patients were recruited from Department of Endocrinology at Taizhou People&#x02019;s Hospital, all of whom met the diagnostic criteria for T2DM. Out of these patients, 35 were identified as having MCI and were subsequently allocated to the MCI group. The remaining 70 patients who exhibited normal cognitive function were allocated to the control group. Prior to participation in the study, all participants were provided with information regarding the purpose and procedures of the investigation, and subsequently provided informed consent by signing their name. This study was ethically approved by the Ethics Committee for Medical Research at Taizhou People&#x02019;s Hospital (Approval No.: 202,204,601). All study participants met the World Health Organization&#x02019;s 1999 Criteria for diabetes [<xref ref-type="bibr" rid="CR33">33</xref>] and had a diabetes duration of over three years. Of the recruited participants, 35 met the criteria for MCI according to the MCI Working Group of the European Consortium on Alzheimer&#x02019;s disease [<xref ref-type="bibr" rid="CR34">34</xref>]. The remaining 70 participants did not meet the criteria for MCI but were included in the control group as they satisfied the standards for T2DM. The exclusion criteria were consistent with those used in a previous study [<xref ref-type="bibr" rid="CR35">35</xref>] and specific described as bellow. (a) Recent diagnosed acute complications of diabetes; (b) severe low plasma glucose; (c) acute vascular disease of heart and brain; (d) alcohol or drug abuse; (e) diagnosed disease of thyroid (with thyroid dysfunction or abnormal autoimmune antibodies); (f) severe infection, major surgery, (g) visual or hearing dysfunction (cannot finish neuropsychological tests); (h) depression and dementia (severe cognitive decline out of the range of MCI); (i) smoking and drinking; (j) other diseases may affect (or potentially influence) cognition; cognitive function testing and inflammation, like thyroid function disorder, anemia, cancer, and autoimmune disease (e.g., Crohn&#x02019;s disease, rheumatoid arthritis, systemic lupus erythematosus, and so on).</p></sec><sec id="Sec11"><title>Clinical data collection</title><p id="Par22">The study collected clinical data from patients, including age, gender, duration of education and diabetes. Anthropometric measurements, such as weight and height, were taken upon the patients&#x02019; admission to the hospital, and body mass index (BMI) was calculated using the formula weight (kg)/height (m)<sup>2</sup>. Blood samples were collected on the second day of hospitalization to measure fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) at the Center Laboratory of Taizhou People&#x02019;s Hospital, for medical purposes. All data were obtained from the medical history of the patients. The measurement of IL-5 levels is described in detail above.</p></sec><sec id="Sec12"><title>Human neuropsychological tests</title><p id="Par23">Human neuropsychological tests were performed according to our previous study [<xref ref-type="bibr" rid="CR36">36</xref>]. The assessment of global cognitive abilities in this study was conducted using the MoCA scores. In cases where the education duration was less than 12 years, an additional score of 1 was added to the MoCA scores. The calculation of MoCA scores followed a previously reported method [<xref ref-type="bibr" rid="CR37">37</xref>]. Information processing speed function was measured using the TMTA in accordance with a previous study [<xref ref-type="bibr" rid="CR38">38</xref>]. The executive function was evaluated using the Digit Span Test (DST) [<xref ref-type="bibr" rid="CR39">39</xref>], Verbal Fluency Test (VFT) [<xref ref-type="bibr" rid="CR40">40</xref>] and Trail Making Test-B (TMTB) [<xref ref-type="bibr" rid="CR38">38</xref>], based on previous studies. The function of scene memory was detected using the Logical Memory Test (LMT) [<xref ref-type="bibr" rid="CR41">41</xref>].</p></sec><sec id="Sec13"><title>Human sample size calculation</title><p id="Par24">The minimum sample size was calculated using PASS V11.0.7 (NCSS, USA). Upon completion of participants recruitment, the minimum sample size was estimated based on the ratio of patients in the MCI group to those in the control group, as well as the mean and standard deviation of IL-5 levels. Given a ratio of 1:2 between the MCI and control groups, the minimum sample sizes for the control and MCI groups were estimated to be 41 and 21 participants, respectively.</p></sec><sec id="Sec14"><title>Statistical methods</title><p id="Par25">SPSS 22.0 (IBM, USA) was used for data analysis. Normally distributed variables in two groups were described as mean and standard deviation and compared Student&#x02019;s t tests. Asymmetrically distributed variables in two groups were described as median and interquartile range and compared by nonparametric Mann&#x02013;Whitney U tests. Binary variables were described as frequency and percentage. Their difference in two group was compared by chi-squared test. Pearson and partial correlation analyses was performed with or without adjust the factors (age and gender), respectively, in all patients and patients with MCI. Additionally, binary logistic analysis was employed to find the risk factors of MCI. Additionally, multiple linear regression was performed to explore the factors influence global cognitive function and information processing speed function. Finally, the diagnosis cut-off point and diagnosis values were also evaluated by from ROC curve (In this process, the highest J point is calculated by Youden&#x02019;s index) [<xref ref-type="bibr" rid="CR42">42</xref>].</p></sec></sec><sec id="Sec15"><title>Results</title><sec id="Sec16"><title>Compare of the cognitive performance between mice with or without diabetes</title><p id="Par26">Hyperglycemia stands as a pivotal risk factor for cognitive dysfunction in both human subjects [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>] and animal models afflicted with diabetes mellitus [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. In pursuit of substantiating this assertion and elucidating potential underlying mechanisms, the present study employed db/db mice. Analogous to individuals with T2DM, db/db mice manifested heightened body weights and hyperglycemia (refer to Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A and B). Subsequent experimentation involving a water maze was conducted to assess cognitive performance. Notably, in comparison to their non-diabetic counterparts (db/m mice), db/db mice exhibited a significant decline in cognitive function. This was evidenced by notably shorter escape latencies and path lengths observed in the diabetic mice group (refer to Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>C and D). Furthermore, discernible distinctions were observed in the reduced frequency of crossing the platform area (refer to Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>E and F) and the percentage of time spent in the target quadrant (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>G) when comparing db/db mice to their non-diabetic counterparts. Despite an observable reduction in swimming velocity among diabetic mice, the incongruity relative to non-diabetic mice failed to achieve statistical significance (refer to Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>H).</p><p id="Par27">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Cognitive performance and RNA-seq results of mice with and without diabetes. Notes for Fig.&#x000a0;1: <sup>*</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, <sup>**</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01; Fig.&#x000a0;1A and B showed the difference of body weight and fasting plasma glucose of db/db mice and db/m mice. Figure&#x000a0;1&#x000a0;C and 1D showed the difference of escape latency and path length of db/db mice and db/m mice. Figure&#x000a0;1E showed the trajectory of movement in water maze of db/db mice and db/m mice. Figure&#x000a0;1&#x000a0;F and 1G showed the difference of frequency of crossing the platform area and percentage of the time spent in the target quadrant of db/db mice and db/m mice. Figure&#x000a0;1&#x000a0;H showed the difference of swimming speed of db/db mice and db/m mice. Figure&#x000a0;1I showed the heatmap of RNA-seq results of db/db mice and db/m mice. Figue 1&#x000a0;J and 1&#x000a0;K showed the scatter plot and volcano plot of db/db mice VS db/m mice</p></caption><graphic xlink:href="40618_2024_2430_Fig1_HTML" id="d33e504"/></fig>
</p></sec><sec id="Sec17"><title>Analysis of differentially expressed genes</title><p id="Par28">To elucidate the differentially expressed genes (DEGs) between db/m mice without diabetes and ab/db mice with diabetes, a negative binomial distribution test was conducted to examine the difference in the number of reads. Genes meeting the criteria of an adjusted <italic>P</italic>-value&#x02009;&#x0003c;&#x02009;0.05 and a fold change exceeding two were considered significant. The analysis revealed a total of 745 DEGs between db/m mice and db/db mice. Specifically, in comparison to db/m mice, 553 genes exhibited significant up-regulation, while 192 genes displayed significant down-regulation in db/db mice. The resulting gene expression profiles were visually represented through a cluster heatmap, a scatter plot, and a volcano plot (refer to Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>I, J and K). The detailed catalog of the 745 DEGs can be found in Table file1.</p></sec><sec id="Sec18"><title>KEGG enrichment analysis</title><p id="Par29">The biological pathway analysis referred to the KEGG database (<ext-link ext-link-type="uri" xlink:href="http://www.genome.jp/">http://www.genome.jp/</ext-link>). The top 10 most enriched pathways were Intestinal immune network for IgA production, African trypanosomiasis, Inflammatory bowel disease, Transporters BR, Th1 and Th2 cell differentiation, Type 1 diabetes mellitus, Asthma, Cytokine receptors BR, Cytokine-cytokine receptor interaction, and Allograft rejection (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). As described in the section of introduction, there is a close association between inflammatory and cognitive dysfunction in diabetes. Therefore, in the KEGG analysis, we focused on signaling pathways related to inflammation, with &#x0201c;Intestinal immune network for IgA production&#x0201d; ranking as the top pathway. Within this pathway, the level of IL 5 is significantly elevated in hippocampus of db/db mice, compared with db/m mice.</p><p id="Par30">
<fig id="Fig2"><label>Fig. 2</label><caption><p>KEGG pathway analysis of DEGs in db/db mice and db/m mice. Notes for Fig.&#x000a0;2: The size of bubbles represents the number of genes in the pathway, while the color of bubbles represents <italic>P</italic>-value</p></caption><graphic xlink:href="40618_2024_2430_Fig2_HTML" id="d33e540"/></fig>
</p></sec><sec id="Sec19"><title>GO enrichment analysis</title><p id="Par31">To interpret the possible biological roles of the DEGs in db/m mice and db/db mice, we made function annotation for each gene through GO functional enrichment analysis (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). As for the biological process (BP), the genes were mainly enriched in Antigen processing and presentation of exogenous peptide antigen via MHC class II, Monocarboxylic acid transport, Antigen processing and presentation of peptide or polysaccharide antigen via MHC class II, Positive regulation of B cell proliferation, Acute-phase response, Immune response, Dopaminergic neuron differentiation, Glomerular filtration, Positive regulation of type 2 immune response, and Nucleosome assembly. Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> lists the main GO terms that were enriched in the differentially regulated genes. Consequently, it was found that IL-5 involve in the top 1 KEGG pathway (Intestinal immune network for IgA production) and top 3 GO pathway (Antigen processing and presentation of peptide or polysaccharide antigen via MHC class II). So, the expression IL-5 was investigated in this present study.</p><p id="Par32">
<fig id="Fig3"><label>Fig. 3</label><caption><p>GO pathway analysis of DEGs in db/db mice and db/m mice. Notes for Fig.&#x000a0;3: The red bars represent the Biological Process (BP). The green bars represent the Cellular Component (CC) while the blue represent the Molecular Function (MF)</p></caption><graphic xlink:href="40618_2024_2430_Fig3_HTML" id="d33e562"/></fig>
</p></sec><sec id="Sec20"><title>Validation of RNA-seq results</title><p id="Par33">Real-time PCR was executed on cDNA samples to substantiate the expression profiles of IL-5 mRNA. Notably, our investigation revealed a marked increment in the levels of IL-5 mRNA within the hippocampal tissue of db/db mice in comparison to their db/m counterparts (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A). Furthermore, a similar expression pattern was discerned in the protein levels of IL-5 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>B and C), emanating from the expression of the IL-5 gene, mirroring the observed profile of IL-5 mRNA.</p><p id="Par34">
<fig id="Fig4"><label>Fig. 4</label><caption><p>IL-5 levels and neuroinflammation of mice with and without diabetes. Notes for Fig.&#x000a0;4: <sup>*</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, <sup>**</sup><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01; Fig.&#x000a0;4A showed the IL-5 mRNA levels in db/db mice and db/m mice. Figure&#x000a0;4B showed the image of western blotting for IL-5, while Fig.&#x000a0;4C represent results of western blotting showed in Fig.&#x000a0;4B. Figure&#x000a0;4D showed levels of IL-5 in plasma of db/db mice and db/m mice. Figure&#x000a0;4E F showed the association between IL-5 levels in plasma and frequency of crossing the platform area (or percentage of time spent in the target quadrant) in mice. Figure&#x000a0;4G showed the correlation between IL-5 levels in plasma and swimming speed in mice. Figure&#x000a0;4&#x000a0;H showed the co-location of IBA-1 and CD68 in hippocampus of db/db mice and db/m mice. Figure&#x000a0;4I, 4&#x000a0;J, 4&#x000a0;K and 4&#x000a0;L showed TNF-&#x00251;, IL-6, IL-1&#x003b2;, and IL-10 levels in hippocampus of db/db mice and db/m mice</p></caption><graphic xlink:href="40618_2024_2430_Fig4_HTML" id="d33e592"/></fig>
</p></sec><sec id="Sec21"><title>Levels of IL-5 in plasma of mice without and with diabetes</title><p id="Par35">In addition to the assessment of IL-5 levels within the hippocampus, quantification of protein levels in the plasma of mice was conducted. Analogous to the observed trend in the hippocampus, the IL-5 levels in the plasma of diabetic mice exhibited a statistically significant increase when compared to their nondiabetic counterparts (depicted in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>D). Moreover, noteworthy correlations were established between IL-5 levels in plasma and behavioral parameters, specifically the frequency of crossing the platform area (depicted in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>E) and the percentage of time spent in the target quadrant (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>F). While the statistical analysis did not reveal a significance in the association between IL-5 levels and swimming speed, it is pertinent to note that the overall profiles of these variables demonstrated a similar pattern (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>G).</p></sec><sec id="Sec22"><title>Neuroinflammation in hippocampus of mice without and with diabetes</title><p id="Par36">The present study investigates the association of IL-5 with inflammation and its neuroprotective effects on the neuroinflammation within the hippocampus of murine subjects, with and without diabetes. Intriguingly, immunofluorescence analysis coupled with confocal microscopy revealed a heightened presence of CD68 co-localized with IBA-1 in the hippocampus of mice (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>H). Furthermore, quantitative assessment of isolated hippocampal protein demonstrated elevated levels of pro-inflammatory cytokines, namely TNF-&#x00251; (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>I), IL-6 (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>J), and IL-1&#x003b2; (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>K) concomitant with a reduction in the anti-inflammatory cytokine IL-10 (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>L). These findings underscore the putative involvement of IL-5 in modulating neuroinflammatory processes within the hippocampus, particularly in the diabetic condition.</p></sec><sec id="Sec23"><title>Comparison of clinical characteristics in T2DM patients with and without MCI</title><p id="Par37">In this present study, we firstly analyzed the clinical data of recruited patients with T2DM. As a cross-sectional study, the age and gender of patients in MCI group differ from those of patients in control group. Our results showed that patients with MCI were significantly older than those with normal cognition (<italic>P</italic>&#x02009;=&#x02009;0.004), and the percentage of females in the control group was significantly higher than in the MCI group (<italic>P</italic>&#x02009;=&#x02009;0.010). However, all other relevant factors, including education levels, BMI, and levels of HbA1c, FPG, TG, TC, HDL-C, and LDL-C, were well-matched between the two groups (all <italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05), as shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.</p><p id="Par38">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Comparation of clinical parameters, cognitive function preference and IL-5 levels between control and MCI group in patients with T2DM</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Control (<italic>n</italic>&#x02009;=&#x02009;70)</th><th align="left">MCI (<italic>n</italic>&#x02009;=&#x02009;35)</th><th align="left">
<italic>P</italic>
</th></tr></thead><tbody><tr><td align="left">Age (year)</td><td char="." align="char">55.50 (49.00, 59.00)</td><td char="." align="char">59.00 (54.00, 65.00)</td><td align="left">0.004<sup>b*</sup></td></tr><tr><td align="left">Female (n, %)</td><td char="." align="char">20, 28.57</td><td char="." align="char">19, 54.29</td><td align="left">0.010<sup>c*</sup></td></tr><tr><td align="left">Education</td><td char="." align="char">12.00 (9.00, 15.00)</td><td char="." align="char">12.00 (6.00, 12.00)</td><td align="left">0.118<sup>b</sup></td></tr><tr><td align="left">BMI (Kg/m<sup>2</sup>)</td><td char="." align="char">24.99 (22.25, 27.05)</td><td char="." align="char">24.24 (22.50, 25.98)</td><td align="left">0.605<sup>b</sup></td></tr><tr><td align="left">HbA1c (%)</td><td char="." align="char">8.61&#x02009;&#x000b1;&#x02009;1.85</td><td char="." align="char">8.70&#x02009;&#x000b1;&#x02009;1.35</td><td align="left">0.807<sup>a</sup></td></tr><tr><td align="left">FPG</td><td char="." align="char">7.58 (5.95, 10.02)</td><td char="." align="char">7.21 (5.82, 8.94)</td><td align="left">0.373<sup>b</sup></td></tr><tr><td align="left">C peptide</td><td char="." align="char">517.97 (96.95, 692.04)</td><td char="." align="char">414.73 (292.12, 589.00)</td><td align="left">0.210<sup>b</sup></td></tr><tr><td align="left">TG (mmol/l)</td><td char="." align="char">1.43 (1.00, 2.24)</td><td char="." align="char">1.49 (0.79, 2.36)</td><td align="left">0.765<sup>b</sup></td></tr><tr><td align="left">TC (mmol/l)</td><td char="." align="char">3.96 (3.52, 4.94)</td><td char="." align="char">4.35 (3.33, 5.36)</td><td align="left">0.552<sup>b</sup></td></tr><tr><td align="left">HDL-C (mmol/l)</td><td char="." align="char">0.97 (0.85, 1.16)</td><td char="." align="char">1.01 (0.90, 1.20)</td><td align="left">0.386<sup>b</sup></td></tr><tr><td align="left">LDL-C (mmol/l)</td><td char="." align="char">2.72&#x02009;&#x000b1;&#x02009;0.82</td><td char="." align="char">2.72&#x02009;&#x000b1;&#x02009;0.75</td><td align="left">0.965<sup>a</sup></td></tr><tr><td align="left">IL-5 (pg/ml)</td><td char="." align="char">22.21&#x02009;&#x000b1;&#x02009;2.57</td><td char="." align="char">23.89&#x02009;&#x000b1;&#x02009;1.87</td><td align="left">0.001<sup>a*</sup></td></tr><tr><td align="left">MoCA</td><td char="." align="char">28.00 (27.00, 28.00)</td><td char="." align="char">23.00 (21.00, 25.00)</td><td align="left">0.000<sup>b*</sup></td></tr><tr><td align="left">DST</td><td char="." align="char">11.00 (10.00, 13.00)</td><td char="." align="char">10.00 (9.00, 12.00)</td><td align="left">0.009<sup>b*</sup></td></tr><tr><td align="left">VFT</td><td char="." align="char">18.00 (16.00, 21.00)</td><td char="." align="char">14.00 (12.00, 17.00)</td><td align="left">0.000<sup>b*</sup></td></tr><tr><td align="left">TMTA</td><td char="." align="char">53.50 (42.50, 70.25)</td><td char="." align="char">75.00 (55.00, 102.00)</td><td align="left">0.000<sup>b*</sup></td></tr><tr><td align="left">TMTB</td><td char="." align="char">137.50 (112.25, 175.00)</td><td char="." align="char">183.00 (143.00, 258.00)</td><td align="left">0.000<sup>b*</sup></td></tr><tr><td align="left">LMT</td><td char="." align="char">9.00 (6.00, 13.25)</td><td char="." align="char">8.00 (4.00, 12.00)</td><td align="left">0.096<sup>b</sup></td></tr></tbody></table><table-wrap-foot><p>Notes:</p><p>a Student&#x02019;s t test was employed for normally distributed variables</p><p>b The Mann-Whitney U test was employed for asymmetrically distributed variables</p><p>c The Chi-square test was employed for categorical variables</p><p>*<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05</p><p>Abbreviations: IL-5, interleukin-5; MCI, mild cognitive impairment; BMI, body mass index; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; TG, triglycerides; TC, Total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; MoCA, Montreal Cognitive Assessment; DST, Digit Span Test; VFT, Verbal Fluency Test; TMTA, Trail Making Test-A; TMTB, Trail Making Test-B; LMT, Logical memory test</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec24"><title>Comparison of IL-5 levels and cognitive preference in T2DM patients with and without MCI</title><p id="Par39">In this study, we aimed to explore the potential role of IL-5 in patients with T2DM who experience MCI. To achieve this objective, we compared the levels of IL-5 in plasma as well as the scores obtained from various cognitive tests, namely MoCA, DST, VFT, TMTA, TMTB, and LMT, between T2DM patients with and without MCI. We found that patients with impaired cognition had significantly elevated levels of IL-5 compared to those with normal cognition (<italic>P</italic>&#x02009;=&#x02009;0.001). Furthermore, we observed that patients with MCI had decreased scores on MoCA, DST, and VFT, while increased scores on TMTA and TMTB, as compared to those without MCI (all <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). Although a decrease in LMT scores was also noted in diabetic patients with cognitive decline, compared to those with T2DM and normal cognition, there was no statistical significance (<italic>P</italic>&#x02009;=&#x02009;0.096) (refer to Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> for detailed results).</p></sec><sec id="Sec25"><title>Association between IL-5 levels and cognitive preference in patients with T2DM</title><p id="Par40">In order to investigate the potential correlation between IL-5 and cognitive function in patients with T2DM, Pearson association analyses were conducted. The results revealed interesting associations between IL-5 levels and MoCA scores (<italic>R</italic> = -0.389, <italic>P</italic>&#x02009;=&#x02009;0.000; <italic>R</italic> = -0.349, <italic>P</italic>&#x02009;=&#x02009;0.040), as well as TMTA scores (<italic>R</italic>&#x02009;=&#x02009;0.192, <italic>P</italic>&#x02009;=&#x02009;0.049; <italic>R</italic>&#x02009;=&#x02009;0.047, <italic>P</italic>&#x02009;=&#x02009;0.013), not only in all patients, but also in patients with MCI. Given the age and gender differences between patients with and without MCI, partial association analyses were also performed, which controlled for these two factors. Interestingly, the results showed that IL-5 levels were positively associated with TMTA scores in both all patients (<italic>R</italic>&#x02009;=&#x02009;0.203, <italic>P</italic>&#x02009;=&#x02009;0.039) and patients with MCI (<italic>R</italic>&#x02009;=&#x02009;0.403, <italic>P</italic>&#x02009;=&#x02009;0.020). Although IL-5 was not found to be significantly associated with MoCA scores in patients with MCI (<italic>R</italic> = -0.304, <italic>P</italic>&#x02009;=&#x02009;0.086), it was significantly related to MoCA scores in all patients (<italic>R</italic> = -0.399, <italic>P</italic>&#x02009;=&#x02009;0.000) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par41">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Association between IL-5 and cognitive function in patients with T2DM</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3"/><th align="left" colspan="4">Model 1</th><th align="left" colspan="4">Model 2</th></tr><tr><th align="left" colspan="2">All</th><th align="left" colspan="2">MCI</th><th align="left" colspan="2">All</th><th align="left" colspan="2">MCI</th></tr><tr><th align="left">R</th><th align="left">P</th><th align="left">R</th><th align="left">P</th><th align="left">R</th><th align="left">P</th><th align="left">R</th><th align="left">P</th></tr></thead><tbody><tr><td align="left">MoCA</td><td align="left">-0.389</td><td align="left">0.000*</td><td align="left">-0.349</td><td align="left">0.040*</td><td align="left">-0.399</td><td align="left">0.000*</td><td align="left">-0.304</td><td align="left">0.086</td></tr><tr><td align="left">DST</td><td align="left">-0.110</td><td align="left">0.266</td><td align="left">-0.112</td><td align="left">0.485</td><td align="left">-0.092</td><td align="left">0.357</td><td align="left">-0.037</td><td align="left">0.837</td></tr><tr><td align="left">VFT</td><td align="left">-0.044</td><td align="left">0.657</td><td align="left">-0.091</td><td align="left">0.605</td><td align="left">-0.037</td><td align="left">0.710</td><td align="left">-0.030</td><td align="left">0.868</td></tr><tr><td align="left">TMTA</td><td align="left">0.192</td><td align="left">0.049*</td><td align="left">0.417</td><td align="left">0.013*</td><td align="left">0.203</td><td align="left">0.039*</td><td align="left">0.403</td><td align="left">0.020*</td></tr><tr><td align="left">TMTB</td><td align="left">-0.182</td><td align="left">0.063</td><td align="left">0.179</td><td align="left">0.302</td><td align="left">0.204</td><td align="left">0.039</td><td align="left">0.173</td><td align="left">0.337</td></tr><tr><td align="left">LMT</td><td align="left">-0.053</td><td align="left">0.592</td><td align="left">-0.239</td><td align="left">0.167</td><td align="left">-0.031</td><td align="left">0.755</td><td align="left">-0.166</td><td align="left">0.356</td></tr></tbody></table><table-wrap-foot><p>Notes:</p><p>Model 1 showed the Pearson association between IL-5 and cognitive preference test scores in all patients and patients with MCI; Model 2 showed the partial association between IL-5 and cognitive preference test scores in all patients and patients with MCI adjusted for age and gender</p><p>*<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05</p><p>Abbreviations: IL-5, interleukin-5; MCI, mild cognitive impairment; MoCA, Montreal Cognitive Assessment; DST, Digit Span Test; VFT, Verbal Fluency Test; TMTA, Trail Making Test-A; TMTB, Trail Making Test-B; LMT, Logical memory test</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec29"><title>Analysis for the risk factor for MCI and the factor influence MoCA and TMTA scores in patients with T2DM</title><p id="Par43">In order to determine whether elevated levels of interleukin-5 (IL-5) serve as a risk factor for MCI in patients diagnosed with T2DM, binary logistic regression analysis was employed. The results indicate that heightened plasma concentrations of IL-5 are indeed a risk factor for MCI in T2DM patients (OR&#x02009;=&#x02009;1.393, <italic>P</italic>&#x02009;=&#x02009;0.002). Additionally, after adjusting for age and gender, elevated levels of IL-5 remained a risk factor for MCI in T2DM patients (OR&#x02009;=&#x02009;1.472, <italic>P</italic>&#x02009;=&#x02009;0.003) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). The present study conducted a multiple linear regression analysis to examine the relationship between IL-5 level and cognitive function as measured by the MoCA and the TMTA. The results indicated that IL-5 was a significant factor that influenced both MoCA score (<italic>P</italic>&#x02009;=&#x02009;0.000) and TMTA score (<italic>P</italic>&#x02009;=&#x02009;0.049) when age and gender were not adjusted for. After adjusting for age and gender, IL-5 remained a significant factor that impacted MoCA score (<italic>P</italic>&#x02009;=&#x02009;0.000) and also affected TMTA score in patients withT2DM (<italic>P</italic>&#x02009;=&#x02009;0.039) (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).</p><p id="Par44">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>IL-5 is an independent risk factor for MCI in patients with T2DM</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">&#x003b2;</th><th align="left">OR</th><th align="left">
<italic>P</italic>
</th></tr></thead><tbody><tr><td align="left">Model 1</td><td char="." align="char">0.331</td><td char="." align="char">1.393</td><td char="." align="char">0.002*</td></tr><tr><td align="left">Model 2</td><td char="." align="char">0.386</td><td char="." align="char">1.472</td><td char="." align="char">0.003*</td></tr></tbody></table><table-wrap-foot><p>Notes:</p><p>Model 1 showed that IL-5 is a risk factor for MCI without the adjusting for age and gender; Model 2 showed that IL-5 is a risk factor for MCI adjusting for age and gender</p><p>*<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05</p><p>Abbreviations: IL-5, interleukin-5; MCI, mild cognitive impairment</p></table-wrap-foot></table-wrap>
</p><p id="Par45">
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Analysis for factors influence the TMTA scores of T2DM patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" rowspan="2"/><th align="left" rowspan="2">&#x003b2;</th><th align="left" colspan="2">95% CL for &#x003b2;</th><th align="left" rowspan="2">P</th></tr><tr><th align="left">lower</th><th align="left">upper</th></tr></thead><tbody><tr><td align="left" rowspan="2">MoCA</td><td align="left">Model 1</td><td char="." align="char">-0.389</td><td align="left">-0.749</td><td align="left">-0.275</td><td align="left">0.000*</td></tr><tr><td align="left">Model 2</td><td char="." align="char">-0.363</td><td align="left">-0.694</td><td align="left">-0.261</td><td align="left">0.000*</td></tr><tr><td align="left" rowspan="2">TMTA</td><td align="left">Model 1</td><td char="." align="char">0.192</td><td align="left">0.009</td><td align="left">5.081</td><td align="left">0.049*</td></tr><tr><td align="left">Model 2</td><td char="." align="char">0.171</td><td align="left">0.112</td><td align="left">4.401</td><td align="left">0.039*</td></tr></tbody></table><table-wrap-foot><p>Notes:</p><p>Model 1 indicated that IL-5 was a significant factor that influenced both MoCA score and TMTA score when age and gender were not adjusted for; Model 2 indicated that IL-5 was a significant factor that influenced both MoCA score and TMTA score after adjusting for age and gender</p><p>*<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05</p><p>Abbreviations: TMTA, Trail Making Test-A; T2DM, type 2 diabetes mellitus; IL-5, interleukin-5</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec26"><title>Evaluation the diagnosis values of IL-5 for MCI in patients with T2DM</title><p id="Par46">As an increased level of IL-5 has been identified as a potential risk factor for MCI in patients with T2DM, we conducted a detailed investigation to ascertain the diagnostic utility of IL-5. Using ROC curve analysis, we determined the diagnostic cut-off value for IL-5 to be 22.98 pg/ml (with the highest J point of Youden&#x02019;s index: 0.415). Furthermore, our analysis revealed a sensitivity of 68.6% and specificity of 72.90% for the established cut-off value (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>).</p><p id="Par47">
<fig id="Fig5"><label>Fig. 5</label><caption><p>ROC curve of IL-5 for the sensitivity and specificity of MCI. Notes for Fig.&#x000a0;5: It is determined that the diagnostic cut-off value for IL-5 to be 22.98 pg/ml, revealed a sensitivity of 68.6% and specificity of 72.90%. The area under the curve is 0.711. The highest J point of Youden&#x02019;s index is 0.415. Abbreviations: ROC, receiver operating characteristic; IL-5, interleukin-5; MCI, mild cognitive impairment</p></caption><graphic xlink:href="40618_2024_2430_Fig5_HTML" id="d33e1332"/></fig>
</p></sec></sec><sec id="Sec27"><title>Discussion</title><p id="Par48">The rising prevalence of diabetes has led to an increased focus on its complications, owing to their significant economic burden [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. MCI is one of the most important complications of diabetes, which if left untreated, can progress to dementia. However, this disease exhibits a hidden onset, mild symptoms, and lacks effective biomarkers, leading to delayed diagnosis [<xref ref-type="bibr" rid="CR49">49</xref>]. The hippocampus is recognized as a crucial organ underlying cognitive functions. Numerous studies have demonstrated structural and functional impairments in the hippocampus of individuals suffering from cognitive dysfunction [<xref ref-type="bibr" rid="CR50">50</xref>&#x02013;<xref ref-type="bibr" rid="CR52">52</xref>]. Our research also reveals that hippocampal tissues in diabetic mice with cognitive impairments exhibit excessive phosphorylation of Tau protein, a hallmark of cognitive dysfunction in diabetes [<xref ref-type="bibr" rid="CR53">53</xref>].</p><p id="Par49">In this study, we first compared the RNA-seq results of hippocampal tissues from diabetic mice and control mice. We then validated the sequencing results using PCR. Subsequently, we confirmed these results at the protein level. Through clinical experiments, we verified the correlation between IL-5 and cognitive impairment, and evaluated the diagnostic value of IL-5 for MCI in patients with T2DM (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>).</p><p id="Par50">
<fig id="Fig6"><label>Fig. 6</label><caption><p>The main content of the research. Notes for Fig.&#x000a0;6: In this study, we first compared the RNA-seq results between diabetic mice (db/db mice) and control mice (db/dm mice). We then validated these sequencing results at both the mRNA and protein levels. Finally, we conducted clinical results to confirm the correlation between IL-5 and cognitive impairment and assessed the diagnostic value of IL-5 for MCI in patients with T2DM</p></caption><graphic xlink:href="40618_2024_2430_Fig6_HTML" id="d33e1370"/></fig>
</p><p id="Par51">Firstly, in our present study, we initially employed transcriptome sequencing to elucidate the genes associated with changes in the hippocampal tissues of diabetic mice with cognitive dysfunction. As stated in the introduction, the emergence of diabetic MCI may stem from neuroinflammation [<xref ref-type="bibr" rid="CR54">54</xref>]. Additionally, due to the significant involvement of inflammatory responses in cognitive impairment and metabolic disorders [<xref ref-type="bibr" rid="CR55">55</xref>&#x02013;<xref ref-type="bibr" rid="CR57">57</xref>], particular attention was directed towards those associated with inflammatory responses. The results indicate that IL-5 is involved in the top-ranking KEGG pathway (Intestinal immune network for IgA production) and the third-ranking GO pathway (Antigen processing and presentation of peptide or polysaccharide antigen via MHC class II). Consequently, the expression of IL-5 was scrutinized in the current study. Further foundational research unveiled elevated levels of IL-5 not only in the hippocampal tissues but also in the plasma of diabetic mice. Additionally, the increased levels of IL-5 in the plasma demonstrated a correlation with the cognitive function of diabetic mice. Additionally, levels of IL-5 elevated in humans [<xref ref-type="bibr" rid="CR21">21</xref>] and animals [<xref ref-type="bibr" rid="CR58">58</xref>] with diabetes. Increased IL-5 levels have been linked to impaired cognitive function [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>] and may be associated with brain-derived neurotrophic factor [<xref ref-type="bibr" rid="CR25">25</xref>], which plays an essential role in the development of diabetic cognitive impairment [<xref ref-type="bibr" rid="CR59">59</xref>]. Thus, explore the potential links between IL-5 and cognitive function in patients with T2DM, and evaluate the diagnostic value of IL-5 for MCI in T2DM patients.</p><p id="Par52">To the best of our knowledge, this is the first study to analyze the levels of IL-5 and cognitive dysfunction in patients with T2DM. In this present study, we firstly described the clinical characteristics of diabetic patients who were recruited. Although most factors were well-matched, there were differences in age and gender between diabetic participants with and without MCI. Therefore, these two factors were considered in further analysis. Secondly, we confirmed that IL-5 levels were increased in diabetic patients with MCI, which was consistent with studies demonstrating increased IL-5 levels in patients with other diabetic complications [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. Furthermore, we found that IL-5 levels were not only associated with the MoCA scores, which reflect global cognitive function, but also with the TMTA scores, reflecting information processing speed, in patients with T2DM. Moreover, these associations remained significant even after adjusting for age and gender in partial association analysis. These results are consistent with several other studies that have found associations between IL-5 and diabetic nephropathy and diabetic retinopathy [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Additionally, IL-5 is a cytokine associated with inflammation and is released from group II innate lymphoid cells. Previously study indicated an association between lymphocyte and cognitive impairment by a meta-analysis of observational studies [<xref ref-type="bibr" rid="CR62">62</xref>].</p><p id="Par53">In order to validate the relationship between IL-5 and MCI in patients with T2DM, both binary logistic regression and multiple linear regression analyses were conducted. The results indicated that elevated levels of IL-5 are a risk factor for MCI in T2DM patients, with or without adjusting for age and gender. Furthermore, increased IL-5 levels were found to impact not only the overall cognitive function, but also the speed of information processing in patients. These findings are consistent with previous studies that have demonstrated the association between IL-5 levels and cognitive function [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Additionally, the diagnostic values of IL-5 for MCI were calculated, aside from its relationship with cognitive function.</p><p id="Par54">In the present study, we have discovered elevated levels of IL-5 in patients diagnosed with MCI. Our findings have demonstrated that the increased IL-5 expression serves as one of the risk factors for MCI in patients with T2DM. To our knowledge, this is the first study to establish a correlation between IL-5 and cognitive performance in T2DM patients. Our investigations have further indicated that the heightened levels of IL-5 can significantly affect the function of information processing speed. Furthermore, we have conducted the initial evaluation of the diagnostic value of IL-5 for MCI in patients.</p><p id="Par55">In this study, we examined the correlation between IL-5 and cognitive dysfunction in diabetes and explored the potential diagnostic value of IL-5 in diabetic cognitive impairment. However, in the clinical research segment, our IL-5 levels were measured from peripheral blood, neither originating from brain tissue nor cerebrospinal fluid. This may diminish its diagnostic utility. Nevertheless, there may still exist a certain relationship between peripheral blood IL-5 levels and central nervous system IL-5 levels. Firstly, despite the presence of the blood-brain barrier, the central nervous system and peripheral tissues share similar environments; for instance, the levels of glucose in the nervous system are correlated with those in the periphery. Therefore, there may be a correlation in IL-5 levels produced by inflammatory cells in the central nervous system and peripheral organs. Additionally, studies have suggested that in diabetic conditions, the functionality of the blood-brain barrier may be compromised, allowing substances that typically cannot pass through the blood-brain barrier [<xref ref-type="bibr" rid="CR63">63</xref>], such as IL-5, to traverse it. Certain specialized structures, including extracellular vesicles such as exosomes [<xref ref-type="bibr" rid="CR64">64</xref>], might facilitate the transport of IL-5 across the blood-brain barrier.</p><p id="Par56">To the best of our knowledge, this is the first study to explore the relationship between IL-5 and cognitive function in type 2 diabetes patients. In this present study, we not only found a correlation between IL-5 and cognitive function, but also suggest that elevated IL-5 mainly affects the information processing speed of diabetic patients. Furthermore, this study also assessed the value of IL-5 in diagnosing MCI in patients with T2DM for the first time. This research may hold potential value in early detection of cognitive impairment in diabetes. However, this study has several limitations that need to be considered. Firstly, it is a cross-sectional study with unmatched individuals in the control and MCI groups. Therefore, only a correlation between IL-5 and cognitive preference could be demonstrated, rather than a causal relationship. Although further analysis adjusted for age and gender, this limitation must be acknowledged. While IL-5 may serve as a potential biomarker that can be easily detected in peripheral blood, its sensitivity and specificity are only 68.6% and 72.90%, respectively, indicating that additional biomarkers for combined diagnosis are necessary. Secondly, since drug treatments, including diabetes drugs, may have a potential impact on cognitive function [<xref ref-type="bibr" rid="CR65">65</xref>&#x02013;<xref ref-type="bibr" rid="CR67">67</xref>], the medication using of patients should be taken into account. However, among the enrolled patients, we only collected information on the medications they were using at the time of enrollment, without detailed records of dosage, formulation, and duration of medication use. Due to limitations in sample size, some medications were only used by a few patients. Therefore, conducting a detailed analysis of medications is evidently not feasible in our current study. This should be considered a limitation of this work. However, in another study conducted by our former colleagues, the potential impact of different medications on cognitive function was explored through network meta-analysis [<xref ref-type="bibr" rid="CR68">68</xref>]. Thirdly, based on prior research showing the substantial influence of smoking and alcohol consumption on diabetic complications [<xref ref-type="bibr" rid="CR69">69</xref>&#x02013;<xref ref-type="bibr" rid="CR71">71</xref>], we&#x02019;ve omitted smokers and drinkers from our study. While exploring the impact of smoking and alcohol consumption on cognitive function is intriguing, we did not include patients engaging in these behaviors as it was not the focus of our study, which could be considered a limitation. Similarly, secondhand smoke may also potentially affect the nervous system [<xref ref-type="bibr" rid="CR72">72</xref>], yet due to a lack of exploring strategy, our study did not address this issue, which can also be viewed as a limitation of our study. Lastly, mechanistically, the binding of IL-5 to its receptor recruit phosphorylation of JAK. The phosphorylation of JAK can further activate the JAK-STAT signaling pathway in a cascade manner. The JAK-STAT signaling pathway may be involved in cell apoptosis, including neurons [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. Although our research has demonstrated the correlation between IL-5 and cognitive impairments in diabetes, the activation and involvement of the IL-5-associated JAK-STAT signaling pathway in neuronal apoptosis and its contribution to cognitive impairments in diabetes are still subject to further investigation.</p></sec><sec id="Sec28"><title>Conclusion</title><p id="Par57">Generally, the evidence suggests that IL-5 is linked to cognitive impairment in individuals with T2DM. Elevated levels of IL-5 represent a potential risk factor for MCI in T2DM patients, specifically affecting information processing speed. The identified diagnostic threshold for IL-5 in relation to MCI is 22.98 pg/ml, and may hold promise as a biomarker for individuals with T2DM. While our study has explored the potential utility of IL-5 as a biomarker for MCI in patients with T2DM, further investigation through large-scale research endeavors is warranted to comprehensively assess its clinical applicability.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Hui Zhang, Wenwen Zhu and Shufang Yang contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was partially supported by China Postdoctoral Science Foundation (Haoqiang Zhang, 2024M753132),&#x000a0;China Endocrine Metabolism Talent Research Project from China International Medical Foundation (Haoqiang Zhang, 2023-N-03-12), and Research Funds of Center for Leading Medicine and Advanced Technologies of IHM (Haoqiang Zhang, 2023IHM02006),&#x000a0;Chinese Cardiovascular Association-Natural lipid-lowering drugs fund (Haoqiang Zhang,&#x000a0;2023-CCA-NLD-820), Scientific Research Start-up Funds of The First Affiliated Hospital of USTC (Haoqiang Zhang, RC2021178),&#x000a0;and Taizhou People&#x02019;s Hospital Hospital-level Scientific Research Fund Project (Shufang Yang, ZL202219).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>All authors made significant contributions to the work reported. Haoqiang Zhang contributed to the idea. Hui Zhang, Wenwen Zhu, and Shufang Yang wrote the manuscript draft. Hui Zhang, Wenwen Zhu, Shufang Yang, Tong Niu, Huzaifa Fareeduddin Mohammed Farooqui, Bing Song, Hongxiao Wang, Sumei Li, Jumei Wang, Linlin Xu, Zhen Zhang collected the data, or performed the tests and (or) statistical analysis and (or) revised the manuscript. All authors gave final approval of the version to be published, agreed on the journal to which the article has been submitted, and agreed to be accountable for all aspects of the work.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data in this manuscript have been submitted to The First Affiliated Hospital of USTC for records. All data are available on reasonable request from corresponding authors.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interest</title><p id="Par63">The authors report no interest conflicts in this work.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Magliano DJ, Boyko EJ (2021) IDF DIABETES ATLAS, 10th edn. Brussels</mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name></person-group><article-title>Inflammation-related epigenetic modification: the Bridge between Immune and Metabolism in Type 2 diabetes</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>883410</fpage><pub-id pub-id-type="pmid">35603204</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Ding Q, Gao Z, Chen K, Zhang Q, Hu S, Zhao L (2022) Inflammation-related epigenetic modification: the Bridge between Immune and Metabolism in Type 2 diabetes. Front Immunol 13:883410<pub-id pub-id-type="pmid">35603204</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Abi Saleh</surname><given-names>R</given-names></name><name><surname>Lirette</surname><given-names>ST</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Fornage</surname><given-names>M</given-names></name><name><surname>Turner</surname><given-names>ST</given-names></name><name><surname>Hammond</surname><given-names>PI</given-names></name><name><surname>Mosley</surname><given-names>TH</given-names></name><name><surname>Griswold</surname><given-names>ME</given-names></name><name><surname>Windham</surname><given-names>BG</given-names></name></person-group><article-title>Mediation effects of diabetes and inflammation on the relationship of obesity to cognitive impairment in African americans</article-title><source>J Am Geriatr Soc</source><year>2022</year><volume>70</volume><issue>10</issue><fpage>3021</fpage><lpage>3029</lpage><pub-id pub-id-type="pmid">35941823</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Abi Saleh R, Lirette ST, Benjamin EJ, Fornage M, Turner ST, Hammond PI, Mosley TH, Griswold ME, Windham BG (2022) Mediation effects of diabetes and inflammation on the relationship of obesity to cognitive impairment in African americans. J Am Geriatr Soc 70(10):3021&#x02013;3029<pub-id pub-id-type="pmid">35941823</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Guzman-Ramos</surname><given-names>K</given-names></name><name><surname>Osorio-Gomez</surname><given-names>D</given-names></name><name><surname>Bermudez-Rattoni</surname><given-names>F</given-names></name></person-group><article-title>Cognitive impairment in Alzheimer&#x02019;s and metabolic diseases: a Catecholaminergic hypothesis</article-title><source>Neuroscience</source><year>2022</year><volume>497</volume><fpage>308</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">35654292</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Guzman-Ramos K, Osorio-Gomez D, Bermudez-Rattoni F (2022) Cognitive impairment in Alzheimer&#x02019;s and metabolic diseases: a Catecholaminergic hypothesis. Neuroscience 497:308&#x02013;323<pub-id pub-id-type="pmid">35654292</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name></person-group><article-title>Oxidative stress: the nexus of obesity and cognitive dysfunction in diabetes</article-title><source>Front Endocrinol (Lausanne)</source><year>2023</year><volume>14</volume><fpage>1134025</fpage><pub-id pub-id-type="pmid">37077347</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Li H, Ren J, Li Y, Wu Q, Wei J (2023) Oxidative stress: the nexus of obesity and cognitive dysfunction in diabetes. Front Endocrinol (Lausanne) 14:1134025<pub-id pub-id-type="pmid">37077347</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Pansini</surname><given-names>A</given-names></name><name><surname>Lombardi</surname><given-names>A</given-names></name><name><surname>Morgante</surname><given-names>M</given-names></name><name><surname>Frullone</surname><given-names>S</given-names></name><name><surname>Marro</surname><given-names>A</given-names></name><name><surname>Rizzo</surname><given-names>M</given-names></name><name><surname>Martinelli</surname><given-names>G</given-names></name><name><surname>Boccalone</surname><given-names>E</given-names></name><name><surname>De Luca</surname><given-names>A</given-names></name><name><surname>Santulli</surname><given-names>G</given-names></name><etal/></person-group><article-title>Hyperglycemia and physical impairment in Frail Hypertensive older adults</article-title><source>Front Endocrinol (Lausanne)</source><year>2022</year><volume>13</volume><fpage>831556</fpage><pub-id pub-id-type="pmid">35498439</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Pansini A, Lombardi A, Morgante M, Frullone S, Marro A, Rizzo M, Martinelli G, Boccalone E, De Luca A, Santulli G et al (2022) Hyperglycemia and physical impairment in Frail Hypertensive older adults. Front Endocrinol (Lausanne) 13:831556<pub-id pub-id-type="pmid">35498439</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Si</surname><given-names>SC</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Luo</surname><given-names>HY</given-names></name><name><surname>Ma</surname><given-names>YX</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group><article-title>Cognitive decline in elderly patients with type 2 diabetes is associated with glycated albumin, ratio of glycated albumin to glycated hemoglobin, and concentrations of inflammatory and oxidative stress markers</article-title><source>Heliyon</source><year>2023</year><volume>9</volume><issue>12</issue><fpage>e22956</fpage><pub-id pub-id-type="pmid">38058429</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Si SC, Yang W, Luo HY, Ma YX, Zhao H, Liu J (2023) Cognitive decline in elderly patients with type 2 diabetes is associated with glycated albumin, ratio of glycated albumin to glycated hemoglobin, and concentrations of inflammatory and oxidative stress markers. Heliyon 9(12):e22956<pub-id pub-id-type="pmid">38058429</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Bu</surname><given-names>T</given-names></name><name><surname>Bu</surname><given-names>X</given-names></name><name><surname>Ni</surname><given-names>Q</given-names></name></person-group><article-title>Cognitive dysfunction in diabetes: abnormal glucose metabolic regulation in the brain</article-title><source>Front Endocrinol (Lausanne)</source><year>2023</year><volume>14</volume><fpage>1192602</fpage><pub-id pub-id-type="pmid">37396164</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Zhang S, Zhang Y, Wen Z, Yang Y, Bu T, Bu X, Ni Q (2023) Cognitive dysfunction in diabetes: abnormal glucose metabolic regulation in the brain. Front Endocrinol (Lausanne) 14:1192602<pub-id pub-id-type="pmid">37396164</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Mariani</surname><given-names>E</given-names></name><name><surname>Monastero</surname><given-names>R</given-names></name><name><surname>Mecocci</surname><given-names>P</given-names></name></person-group><article-title>Mild cognitive impairment: a systematic review</article-title><source>J Alzheimers Dis</source><year>2007</year><volume>12</volume><issue>1</issue><fpage>23</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">17851192</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Mariani E, Monastero R, Mecocci P (2007) Mild cognitive impairment: a systematic review. J Alzheimers Dis 12(1):23&#x02013;35<pub-id pub-id-type="pmid">17851192</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>H</given-names></name><name><surname>Doi</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Makizako</surname><given-names>H</given-names></name></person-group><article-title>Reversible predictors of reversion from mild cognitive impairment to normal cognition: a 4-year longitudinal study</article-title><source>Alzheimers Res Ther</source><year>2019</year><volume>11</volume><issue>1</issue><fpage>24</fpage><pub-id pub-id-type="pmid">30867057</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Shimada H, Doi T, Lee S, Makizako H (2019) Reversible predictors of reversion from mild cognitive impairment to normal cognition: a 4-year longitudinal study. Alzheimers Res Ther 11(1):24<pub-id pub-id-type="pmid">30867057</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>R</given-names></name><name><surname>Guo</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group><article-title>Increased plasma Interleukin-1beta level is associated with memory deficits in type 2 diabetic patients with mild cognitive impairment</article-title><source>Psychoneuroendocrinology</source><year>2018</year><volume>96</volume><fpage>148</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">29957442</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Tian S, Huang R, Han J, Cai R, Guo D, Lin H, Wang J, Wang S (2018) Increased plasma Interleukin-1beta level is associated with memory deficits in type 2 diabetic patients with mild cognitive impairment. Psychoneuroendocrinology 96:148&#x02013;154<pub-id pub-id-type="pmid">29957442</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Niu</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Fareeduddin Mohammed Farooqui</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group><article-title>Microglial SCAP deficiency protects against diabetes-associated cognitive impairment through inhibiting NLRP3 inflammasome-mediated neuroinflammation</article-title><source>Brain Behav Immun</source><year>2024</year><volume>119</volume><fpage>154</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">38570101</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Zhu W, Zhang H, Niu T, Liu K, Fareeduddin Mohammed Farooqui H, Sun R, Chen X, Yuan Y, Wang S (2024) Microglial SCAP deficiency protects against diabetes-associated cognitive impairment through inhibiting NLRP3 inflammasome-mediated neuroinflammation. Brain Behav Immun 119:154&#x02013;170<pub-id pub-id-type="pmid">38570101</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Zhang H, Huang R, Tian S, An K, Zhu W, Shi J, Cao W, Wang S (2020) The CC Genotype of Insulin-Induced Gene 2 rs7566605 Is a Protective Factor of Hypercholesteremia Susceptible to Mild Cognitive Impairment, Especially to the Executive Function of Patients with Type 2 Diabetes Mellitus. Biomed Res Int. 2020:4935831</mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Niu</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>An</surname><given-names>K</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group><article-title>Inverted U-shaped correlation between serum low-density lipoprotein cholesterol levels and cognitive functions of patients with type 2 diabetes mellitus</article-title><source>Lipids Health Dis</source><year>2021</year><volume>20</volume><issue>1</issue><fpage>103</fpage><pub-id pub-id-type="pmid">34511118</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Zhang H, Zhu W, Niu T, Wang Z, An K, Cao W, Shi J, Wang S (2021) Inverted U-shaped correlation between serum low-density lipoprotein cholesterol levels and cognitive functions of patients with type 2 diabetes mellitus. Lipids Health Dis 20(1):103<pub-id pub-id-type="pmid">34511118</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>S</given-names></name><name><surname>An</surname><given-names>K</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group><article-title>Elevated plasma free fatty acid susceptible to early cognitive impairment in type 2 diabetes Mellitus</article-title><source>J Alzheimers Dis</source><year>2021</year><volume>82</volume><issue>3</issue><fpage>1345</fpage><lpage>1356</lpage><pub-id pub-id-type="pmid">34151809</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Zhu W, Xu L, Zhang H, Tian S, An K, Cao W, Shi J, Tang W, Wang S (2021) Elevated plasma free fatty acid susceptible to early cognitive impairment in type 2 diabetes Mellitus. J Alzheimers Dis 82(3):1345&#x02013;1356<pub-id pub-id-type="pmid">34151809</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Konya</surname><given-names>V</given-names></name><name><surname>Mjosberg</surname><given-names>J</given-names></name></person-group><article-title>Lipid mediators as regulators of human ILC2 function in allergic diseases</article-title><source>Immunol Lett</source><year>2016</year><volume>179</volume><fpage>36</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">27396531</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Konya V, Mjosberg J (2016) Lipid mediators as regulators of human ILC2 function in allergic diseases. Immunol Lett 179:36&#x02013;42<pub-id pub-id-type="pmid">27396531</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Andreotti</surname><given-names>C</given-names></name><name><surname>King</surname><given-names>AA</given-names></name><name><surname>Macy</surname><given-names>E</given-names></name><name><surname>Compas</surname><given-names>BE</given-names></name><name><surname>DeBaun</surname><given-names>MR</given-names></name></person-group><article-title>The Association of Cytokine levels with cognitive function in Children with Sickle Cell Disease and normal MRI studies of the brain</article-title><source>J Child Neurol</source><year>2015</year><volume>30</volume><issue>10</issue><fpage>1349</fpage><lpage>1353</lpage><pub-id pub-id-type="pmid">25512362</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Andreotti C, King AA, Macy E, Compas BE, DeBaun MR (2015) The Association of Cytokine levels with cognitive function in Children with Sickle Cell Disease and normal MRI studies of the brain. J Child Neurol 30(10):1349&#x02013;1353<pub-id pub-id-type="pmid">25512362</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>XX</given-names></name><name><surname>Ge</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>JT</given-names></name><name><surname>Niu</surname><given-names>JW</given-names></name><name><surname>Xia</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>GH</given-names></name></person-group><article-title>Are anti-inflammatory cytokines Associated with cognitive impairment in patients with Insomnia Comorbid with Depression? A pilot study</article-title><source>Nat Sci Sleep</source><year>2021</year><volume>13</volume><fpage>989</fpage><lpage>1000</lpage><pub-id pub-id-type="pmid">34234602</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">He S, Chen XX, Ge W, Yang S, Chen JT, Niu JW, Xia L, Chen GH (2021) Are anti-inflammatory cytokines Associated with cognitive impairment in patients with Insomnia Comorbid with Depression? A pilot study. Nat Sci Sleep 13:989&#x02013;1000<pub-id pub-id-type="pmid">34234602</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>TC</given-names></name><name><surname>Kiffer</surname><given-names>F</given-names></name><name><surname>Groves</surname><given-names>T</given-names></name><name><surname>Anderson</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Hayar</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>MT</given-names></name><name><surname>Rodriguez</surname><given-names>A</given-names></name><name><surname>Allen</surname><given-names>AR</given-names></name></person-group><article-title>Effects of thioTEPA chemotherapy on cognition and motor coordination</article-title><source>Synapse</source><year>2019</year><volume>73</volume><issue>6</issue><fpage>e22085</fpage><pub-id pub-id-type="pmid">30586195</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Alexander TC, Kiffer F, Groves T, Anderson J, Wang J, Hayar A, Chen MT, Rodriguez A, Allen AR (2019) Effects of thioTEPA chemotherapy on cognition and motor coordination. Synapse 73(6):e22085<pub-id pub-id-type="pmid">30586195</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>M</given-names></name><name><surname>Feng</surname><given-names>M</given-names></name><name><surname>Long</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>G</given-names></name></person-group><article-title>Allergic Asthma-Induced Cognitive Impairment is alleviated by Dexamethasone</article-title><source>Front Pharmacol</source><year>2021</year><volume>12</volume><fpage>680815</fpage><pub-id pub-id-type="pmid">34248632</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Ren M, Feng M, Long Z, Ma J, Peng X, He G (2021) Allergic Asthma-Induced Cognitive Impairment is alleviated by Dexamethasone. Front Pharmacol 12:680815<pub-id pub-id-type="pmid">34248632</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Sokolova</surname><given-names>RN</given-names></name><name><surname>Yankova</surname><given-names>RK</given-names></name><name><surname>Abadjieva</surname><given-names>TI</given-names></name><name><surname>Popova</surname><given-names>TA</given-names></name><name><surname>Ivanovska</surname><given-names>MV</given-names></name><name><surname>Murdjeva</surname><given-names>MA</given-names></name><name><surname>Orbetzova</surname><given-names>MM</given-names></name><name><surname>Dermendzhiev</surname><given-names>SM</given-names></name><name><surname>Pavlova</surname><given-names>MV</given-names></name></person-group><article-title>Association between type 2 diabetes, obesity and key Immunological Components of IgE-mediated inflammation</article-title><source>Folia Med (Plovdiv)</source><year>2017</year><volume>59</volume><issue>2</issue><fpage>159</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">28704195</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Sokolova RN, Yankova RK, Abadjieva TI, Popova TA, Ivanovska MV, Murdjeva MA, Orbetzova MM, Dermendzhiev SM, Pavlova MV (2017) Association between type 2 diabetes, obesity and key Immunological Components of IgE-mediated inflammation. Folia Med (Plovdiv) 59(2):159&#x02013;164<pub-id pub-id-type="pmid">28704195</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Hwang</surname><given-names>DK</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Tao</surname><given-names>Y</given-names></name></person-group><article-title>Association between Aqueous cytokines and Diabetic Retinopathy Stage</article-title><source>J Ophthalmol</source><year>2017</year><volume>2017</volume><fpage>9402198</fpage><pub-id pub-id-type="pmid">28680705</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Wu H, Hwang DK, Song X, Tao Y (2017) Association between Aqueous cytokines and Diabetic Retinopathy Stage. J Ophthalmol 2017:9402198<pub-id pub-id-type="pmid">28680705</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Ji</surname><given-names>X</given-names></name><name><surname>Wan</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name></person-group><article-title>Activity of Group 2 Innate Lymphoid Cells is Associated with chronic inflammation and dysregulated metabolic homoeostasis in type 2 Diabetic Nephropathy</article-title><source>Scand J Immunol</source><year>2018</year><volume>87</volume><issue>2</issue><fpage>99</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">29194733</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Lu P, Ji X, Wan J, Xu H (2018) Activity of Group 2 Innate Lymphoid Cells is Associated with chronic inflammation and dysregulated metabolic homoeostasis in type 2 Diabetic Nephropathy. Scand J Immunol 87(2):99&#x02013;107<pub-id pub-id-type="pmid">29194733</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group><article-title>Elevated peripheral brain-derived neurotrophic factor level Associated with decreasing insulin secretion may Forecast Memory Dysfunction in patients with long-term type 2 diabetes</article-title><source>Front Physiol</source><year>2021</year><volume>12</volume><fpage>686838</fpage><pub-id pub-id-type="pmid">35111074</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Huang X, Xie Z, Wang C, Wang S (2021) Elevated peripheral brain-derived neurotrophic factor level Associated with decreasing insulin secretion may Forecast Memory Dysfunction in patients with long-term type 2 diabetes. Front Physiol 12:686838<pub-id pub-id-type="pmid">35111074</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Cheung CKY, Lan LL, Kyaw M, Mak ADP, Chan A, Chan Y, Wu JCY (2018) Up-regulation of transient receptor potential vanilloid (TRPV) and down-regulation of brain-derived neurotrophic factor (BDNF) expression in patients with functional dyspepsia (FD). Neurogastroenterol Motil 30(2)</mixed-citation></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>IH</given-names></name><name><surname>Chung</surname><given-names>WH</given-names></name><name><surname>Wu</surname><given-names>PC</given-names></name><name><surname>Chen</surname><given-names>CB</given-names></name></person-group><article-title>JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>1068260</fpage><pub-id pub-id-type="pmid">36569854</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Huang IH, Chung WH, Wu PC, Chen CB (2022) JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review. Front Immunol 13:1068260<pub-id pub-id-type="pmid">36569854</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Adachi</surname><given-names>T</given-names></name><name><surname>Alam</surname><given-names>R</given-names></name></person-group><article-title>The mechanism of IL-5 signal transduction</article-title><source>Am J Physiol</source><year>1998</year><volume>275</volume><issue>3</issue><fpage>C623</fpage><lpage>633</lpage><pub-id pub-id-type="pmid">9730944</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Adachi T, Alam R (1998) The mechanism of IL-5 signal transduction. Am J Physiol 275(3):C623&#x02013;633<pub-id pub-id-type="pmid">9730944</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Kumari S, Dhapola R, Reddy DH (2023) Apoptosis in Alzheimer&#x02019;s disease: insight into the signaling pathways and therapeutic avenues. Apoptosis</mixed-citation></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Guvenir Celik</surname><given-names>E</given-names></name><name><surname>Eroglu</surname><given-names>O</given-names></name></person-group><article-title>Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line</article-title><source>Mol Biol Rep</source><year>2023</year><volume>50</volume><issue>1</issue><fpage>319</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">36331743</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Guvenir Celik E, Eroglu O (2023) Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line. Mol Biol Rep 50(1):319&#x02013;329<pub-id pub-id-type="pmid">36331743</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Ruganzu</surname><given-names>JB</given-names></name><name><surname>Zheng</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>R</given-names></name><name><surname>Ji</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><etal/></person-group><article-title>TREM2 overexpression rescues cognitive deficits in APP/PS1 transgenic mice by reducing neuroinflammation via the JAK/STAT/SOCS signaling pathway</article-title><source>Exp Neurol</source><year>2021</year><volume>336</volume><fpage>113506</fpage><pub-id pub-id-type="pmid">33065077</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Ruganzu JB, Zheng Q, Wu X, He Y, Peng X, Jin H, Zhou J, Ma R, Ji S, Ma Y et al (2021) TREM2 overexpression rescues cognitive deficits in APP/PS1 transgenic mice by reducing neuroinflammation via the JAK/STAT/SOCS signaling pathway. Exp Neurol 336:113506<pub-id pub-id-type="pmid">33065077</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Chu</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name></person-group><article-title>Liraglutide improved the cognitive function of diabetic mice via the receptor of advanced glycation end products down-regulation</article-title><source>Aging</source><year>2020</year><volume>13</volume><issue>1</issue><fpage>525</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">33298623</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Zhang H, Chu Y, Zheng H, Wang J, Song B, Sun Y (2020) Liraglutide improved the cognitive function of diabetic mice via the receptor of advanced glycation end products down-regulation. Aging 13(1):525&#x02013;536<pub-id pub-id-type="pmid">33298623</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>An</surname><given-names>K</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group><article-title>Glucagon-like peptide-1 attenuated carboxymethyl lysine induced neuronal apoptosis via peroxisome proliferation activated receptor-gamma</article-title><source>Aging</source><year>2021</year><volume>13</volume><issue>14</issue><fpage>19013</fpage><lpage>19027</lpage><pub-id pub-id-type="pmid">34326274</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Zhang H, Song B, Zhu W, Liu L, He X, Wang Z, An K, Cao W, Shi J, Wang S (2021) Glucagon-like peptide-1 attenuated carboxymethyl lysine induced neuronal apoptosis via peroxisome proliferation activated receptor-gamma. Aging 13(14):19013&#x02013;19027<pub-id pub-id-type="pmid">34326274</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Alberti</surname><given-names>KG</given-names></name><name><surname>Zimmet</surname><given-names>PZ</given-names></name></person-group><article-title>Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation</article-title><source>Diabet Med</source><year>1998</year><volume>15</volume><issue>7</issue><fpage>539</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">9686693</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15(7):539&#x02013;553<pub-id pub-id-type="pmid">9686693</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Portet</surname><given-names>F</given-names></name><name><surname>Ousset</surname><given-names>PJ</given-names></name><name><surname>Visser</surname><given-names>PJ</given-names></name><name><surname>Frisoni</surname><given-names>GB</given-names></name><name><surname>Nobili</surname><given-names>F</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Vellas</surname><given-names>B</given-names></name><name><surname>Touchon</surname><given-names>J</given-names></name><name><surname>Disease</surname></name><name><surname>MCIWGotECoAs</surname></name></person-group><article-title>Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer&#x02019;s Disease</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2006</year><volume>77</volume><issue>6</issue><fpage>714</fpage><lpage>718</lpage><pub-id pub-id-type="pmid">16549412</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Portet F, Ousset PJ, Visser PJ, Frisoni GB, Nobili F, Scheltens P, Vellas B, Touchon J, Disease, MCIWGotECoAs (2006) Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer&#x02019;s Disease. J Neurol Neurosurg Psychiatry 77(6):714&#x02013;718<pub-id pub-id-type="pmid">16549412</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Niu</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>An</surname><given-names>K</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Free triiodothyronine levels are related to executive function and scene memory in type 2 diabetes Mellitus patients without diagnosed thyroid diseases</article-title><source>Diabetes Metab Syndr Obes</source><year>2022</year><volume>15</volume><fpage>1041</fpage><lpage>1050</lpage><pub-id pub-id-type="pmid">35411164</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Zhang H, Yang S, Zhu W, Niu T, Wang Z, An K, Xie Z, Wang P, Huang X, Wang C et al (2022) Free triiodothyronine levels are related to executive function and scene memory in type 2 diabetes Mellitus patients without diagnosed thyroid diseases. Diabetes Metab Syndr Obes 15:1041&#x02013;1050<pub-id pub-id-type="pmid">35411164</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Fareeduddin Mohammed Farooqui</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Niu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name></person-group><article-title>Impact of insulin resistance on mild cognitive impairment in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease</article-title><source>Diabetol Metab Syndr</source><year>2023</year><volume>15</volume><issue>1</issue><fpage>229</fpage><pub-id pub-id-type="pmid">37950317</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Zhang H, Fareeduddin Mohammed Farooqui H, Zhu W, Niu T, Zhang Z, Zhang H (2023) Impact of insulin resistance on mild cognitive impairment in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease. Diabetol Metab Syndr 15(1):229<pub-id pub-id-type="pmid">37950317</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Nasreddine</surname><given-names>ZS</given-names></name><name><surname>Phillips</surname><given-names>NA</given-names></name><name><surname>Bedirian</surname><given-names>V</given-names></name><name><surname>Charbonneau</surname><given-names>S</given-names></name><name><surname>Whitehead</surname><given-names>V</given-names></name><name><surname>Collin</surname><given-names>I</given-names></name><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Chertkow</surname><given-names>H</given-names></name></person-group><article-title>The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment</article-title><source>J Am Geriatr Soc</source><year>2005</year><volume>53</volume><issue>4</issue><fpage>695</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">15817019</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695&#x02013;699<pub-id pub-id-type="pmid">15817019</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Crowe</surname><given-names>SF</given-names></name></person-group><article-title>The differential contribution of mental tracking, cognitive flexibility, visual search, and motor speed to performance on parts a and B of the trail making test</article-title><source>J Clin Psychol</source><year>1998</year><volume>54</volume><issue>5</issue><fpage>585</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">9696108</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Crowe SF (1998) The differential contribution of mental tracking, cognitive flexibility, visual search, and motor speed to performance on parts a and B of the trail making test. J Clin Psychol 54(5):585&#x02013;591<pub-id pub-id-type="pmid">9696108</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>JL</given-names></name><name><surname>Lee</surname><given-names>GT</given-names></name><name><surname>Lam</surname><given-names>YH</given-names></name><name><surname>Chan</surname><given-names>RC</given-names></name><name><surname>Wu</surname><given-names>JY</given-names></name></person-group><article-title>The use of the Digit Span Test in screening for cognitive impairment in acute medical inpatients</article-title><source>Int Psychogeriatr</source><year>2011</year><volume>23</volume><issue>10</issue><fpage>1569</fpage><lpage>1574</lpage><pub-id pub-id-type="pmid">21729426</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Leung JL, Lee GT, Lam YH, Chan RC, Wu JY (2011) The use of the Digit Span Test in screening for cognitive impairment in acute medical inpatients. Int Psychogeriatr 23(10):1569&#x02013;1574<pub-id pub-id-type="pmid">21729426</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YL</given-names></name><name><surname>Chen</surname><given-names>YH</given-names></name><name><surname>Lieh-Mak</surname><given-names>F</given-names></name></person-group><article-title>Semantic verbal fluency deficit as a familial trait marker in schizophrenia</article-title><source>Psychiatry Res</source><year>2000</year><volume>95</volume><issue>2</issue><fpage>133</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">10963799</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Chen YL, Chen YH, Lieh-Mak F (2000) Semantic verbal fluency deficit as a familial trait marker in schizophrenia. Psychiatry Res 95(2):133&#x02013;148<pub-id pub-id-type="pmid">10963799</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Won</surname><given-names>J</given-names></name><name><surname>Callow</surname><given-names>DD</given-names></name><name><surname>Pena</surname><given-names>GS</given-names></name><name><surname>Jordan</surname><given-names>LS</given-names></name><name><surname>Arnold-Nedimala</surname><given-names>NA</given-names></name><name><surname>Nielson</surname><given-names>KA</given-names></name><name><surname>Smith</surname><given-names>JC</given-names></name></person-group><article-title>Hippocampal functional connectivity and memory performance after Exercise intervention in older adults with mild cognitive impairment</article-title><source>J Alzheimers Dis</source><year>2021</year><volume>82</volume><issue>3</issue><fpage>1015</fpage><lpage>1031</lpage><pub-id pub-id-type="pmid">34151792</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Won J, Callow DD, Pena GS, Jordan LS, Arnold-Nedimala NA, Nielson KA, Smith JC (2021) Hippocampal functional connectivity and memory performance after Exercise intervention in older adults with mild cognitive impairment. J Alzheimers Dis 82(3):1015&#x02013;1031<pub-id pub-id-type="pmid">34151792</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Hosseini Mojahed</surname><given-names>F</given-names></name><name><surname>Aalami</surname><given-names>AH</given-names></name><name><surname>Pouresmaeil</surname><given-names>V</given-names></name><name><surname>Amirabadi</surname><given-names>A</given-names></name><name><surname>Qasemi Rad</surname><given-names>M</given-names></name><name><surname>Sahebkar</surname><given-names>A</given-names></name></person-group><article-title>Clinical evaluation of the diagnostic role of MicroRNA-155 in breast Cancer</article-title><source>Int J Genomics</source><year>2020</year><volume>2020</volume><fpage>9514831</fpage><pub-id pub-id-type="pmid">32964011</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Hosseini Mojahed F, Aalami AH, Pouresmaeil V, Amirabadi A, Qasemi Rad M, Sahebkar A (2020) Clinical evaluation of the diagnostic role of MicroRNA-155 in breast Cancer. Int J Genomics 2020:9514831<pub-id pub-id-type="pmid">32964011</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Hua</surname><given-names>S</given-names></name><name><surname>Liao</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>F</given-names></name></person-group><article-title>An updated meta-analysis of cohort studies: diabetes and risk of Alzheimer&#x02019;s disease</article-title><source>Diabetes Res Clin Pract</source><year>2017</year><volume>124</volume><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">28088029</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Zhang J, Chen C, Hua S, Liao H, Wang M, Xiong Y, Cao F (2017) An updated meta-analysis of cohort studies: diabetes and risk of Alzheimer&#x02019;s disease. Diabetes Res Clin Pract 124:41&#x02013;47<pub-id pub-id-type="pmid">28088029</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Strachan</surname><given-names>MW</given-names></name><name><surname>Reynolds</surname><given-names>RM</given-names></name><name><surname>Marioni</surname><given-names>RE</given-names></name><name><surname>Price</surname><given-names>JF</given-names></name></person-group><article-title>Cognitive function, dementia and type 2 diabetes mellitus in the elderly</article-title><source>Nat Rev Endocrinol</source><year>2011</year><volume>7</volume><issue>2</issue><fpage>108</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">21263438</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Strachan MW, Reynolds RM, Marioni RE, Price JF (2011) Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol 7(2):108&#x02013;114<pub-id pub-id-type="pmid">21263438</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Hierro-Bujalance</surname><given-names>C</given-names></name><name><surname>Infante-Garcia</surname><given-names>C</given-names></name><name><surname>Del Marco</surname><given-names>A</given-names></name><name><surname>Herrera</surname><given-names>M</given-names></name><name><surname>Carranza-Naval</surname><given-names>MJ</given-names></name><name><surname>Suarez</surname><given-names>J</given-names></name><name><surname>Alves-Martinez</surname><given-names>P</given-names></name><name><surname>Lubian-Lopez</surname><given-names>S</given-names></name><name><surname>Garcia-Alloza</surname><given-names>M</given-names></name></person-group><article-title>Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer&#x02019;s disease and type 2 diabetes</article-title><source>Alzheimers Res Ther</source><year>2020</year><volume>12</volume><issue>1</issue><fpage>40</fpage><pub-id pub-id-type="pmid">32264944</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Hierro-Bujalance C, Infante-Garcia C, Del Marco A, Herrera M, Carranza-Naval MJ, Suarez J, Alves-Martinez P, Lubian-Lopez S, Garcia-Alloza M (2020) Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer&#x02019;s disease and type 2 diabetes. Alzheimers Res Ther 12(1):40<pub-id pub-id-type="pmid">32264944</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Park KA, Jin Z, Lee JY, An HS, Choi EB, Kim KE, Shin HJ, Jeong EA, Min KA, Shin MC et al (2020) Long-lasting Exendin-4 Fusion protein improves memory deficits in High-Fat Diet/Streptozotocin-Induced Diabetic mice. Pharmaceutics 12(2)</mixed-citation></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Teng</surname><given-names>D</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Qin</surname><given-names>G</given-names></name><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Quan</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Ba</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><etal/></person-group><article-title>Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study</article-title><source>BMJ</source><year>2020</year><volume>369</volume><fpage>m997</fpage><pub-id pub-id-type="pmid">32345662</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H, Shi B, Sun H, Ba J, Chen B et al (2020) Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ 369:m997<pub-id pub-id-type="pmid">32345662</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Saeedi</surname><given-names>P</given-names></name><name><surname>Karuranga</surname><given-names>S</given-names></name><name><surname>Pinkepank</surname><given-names>M</given-names></name><name><surname>Ogurtsova</surname><given-names>K</given-names></name><name><surname>Duncan</surname><given-names>BB</given-names></name><name><surname>Stein</surname><given-names>C</given-names></name><name><surname>Basit</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>JCN</given-names></name><name><surname>Mbanya</surname><given-names>JC</given-names></name><etal/></person-group><article-title>IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045</article-title><source>Diabetes Res Clin Pract</source><year>2022</year><volume>183</volume><fpage>109119</fpage><pub-id pub-id-type="pmid">34879977</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC et al (2022) IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119<pub-id pub-id-type="pmid">34879977</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">Ehtewish H, Arredouani A, El-Agnaf O (2022) Diagnostic, Prognostic, and mechanistic biomarkers of diabetes Mellitus-Associated Cognitive decline. Int J Mol Sci 23(11)</mixed-citation></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The Presence and Severity of NAFLD are Associated with cognitive impairment and hippocampal damage</article-title><source>J Clin Endocrinol Metab</source><year>2023</year><volume>108</volume><issue>12</issue><fpage>3239</fpage><lpage>3249</lpage><pub-id pub-id-type="pmid">37310344</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Miao Y, Zhang B, Sun X, Ma X, Fang D, Zhang W, Wu T, Xu X, Yu C, Hou Y et al (2023) The Presence and Severity of NAFLD are Associated with cognitive impairment and hippocampal damage. J Clin Endocrinol Metab 108(12):3239&#x02013;3249<pub-id pub-id-type="pmid">37310344</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><mixed-citation publication-type="other">Ye D, Miyoshi A, Ushitani T, Kadoya M, Igeta M, Konishi K, Shoji T, Yasuda K, Kitaoka S, Yagi H et al (2023) RAGE in circulating immune cells is fundamental for hippocampal inflammation and cognitive decline in a mouse model of latent chronic inflammation. Brain Behav Immun</mixed-citation></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">Zhao J, Jiao Y, Wang H, Song P, Gao Z, Bing X, Zhang C, Ouyang A, Yao J, Wang S et al (2023) Radiomic features of the hippocampal based on magnetic resonance imaging in the menopausal mouse model linked to neuronal damage and cognitive deficits. Brain Imaging Behav</mixed-citation></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Tian</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group><article-title>Chronic hyperglycemia induces tau hyperphosphorylation by downregulating OGT-involved O-GlcNAcylation in vivo and in vitro</article-title><source>Brain Res Bull</source><year>2020</year><volume>156</volume><fpage>76</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">31931119</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Huang R, Tian S, Zhang H, Zhu W, Wang S (2020) Chronic hyperglycemia induces tau hyperphosphorylation by downregulating OGT-involved O-GlcNAcylation in vivo and in vitro. Brain Res Bull 156:76&#x02013;85<pub-id pub-id-type="pmid">31931119</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="other">Decandia D, Gelfo F, Landolfo E, Balsamo F, Petrosini L, Cutuli D (2023) Dietary Protection against Cognitive Impairment, Neuroinflammation and Oxidative Stress in Alzheimer&#x02019;s Disease Animal Models of Lipopolysaccharide-Induced Inflammation. Int J Mol Sci 24(6)</mixed-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">Litwiniuk A, Bik W, Kalisz M, Baranowska-Bik A (2021) Inflammasome NLRP3 Potentially Links Obesity-Associated Low-Grade Systemic Inflammation and Insulin Resistance with Alzheimer&#x02019;s Disease. Int J Mol Sci 22(11)</mixed-citation></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Ghanbari</surname><given-names>M</given-names></name><name><surname>Momen Maragheh</surname><given-names>S</given-names></name><name><surname>Aghazadeh</surname><given-names>A</given-names></name><name><surname>Mehrjuyan</surname><given-names>SR</given-names></name><name><surname>Hussen</surname><given-names>BM</given-names></name><name><surname>Abdoli Shadbad</surname><given-names>M</given-names></name><name><surname>Dastmalchi</surname><given-names>N</given-names></name><name><surname>Safaralizadeh</surname><given-names>R</given-names></name></person-group><article-title>Interleukin-1 in obesity-related low-grade inflammation: from molecular mechanisms to therapeutic strategies</article-title><source>Int Immunopharmacol</source><year>2021</year><volume>96</volume><fpage>107765</fpage><pub-id pub-id-type="pmid">34015596</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Ghanbari M, Momen Maragheh S, Aghazadeh A, Mehrjuyan SR, Hussen BM, Abdoli Shadbad M, Dastmalchi N, Safaralizadeh R (2021) Interleukin-1 in obesity-related low-grade inflammation: from molecular mechanisms to therapeutic strategies. Int Immunopharmacol 96:107765<pub-id pub-id-type="pmid">34015596</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Denver</surname><given-names>P</given-names></name><name><surname>Gault</surname><given-names>VA</given-names></name><name><surname>McClean</surname><given-names>PL</given-names></name></person-group><article-title>Sustained high-fat diet modulates inflammation, insulin signalling and cognition in mice and a modified xenin peptide ameliorates neuropathology in a chronic high-fat model</article-title><source>Diabetes Obes Metab</source><year>2018</year><volume>20</volume><issue>5</issue><fpage>1166</fpage><lpage>1175</lpage><pub-id pub-id-type="pmid">29316242</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Denver P, Gault VA, McClean PL (2018) Sustained high-fat diet modulates inflammation, insulin signalling and cognition in mice and a modified xenin peptide ameliorates neuropathology in a chronic high-fat model. Diabetes Obes Metab 20(5):1166&#x02013;1175<pub-id pub-id-type="pmid">29316242</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="other">Khudhair Z, Alhallaf R, Eichenberger RM, Field M, Krause L, Sotillo J, Loukas A (2022) Administration of Hookworm Excretory/Secretory Proteins Improves Glucose Tolerance in a mouse model of type 2 diabetes. Biomolecules 12(5)</mixed-citation></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Urbina-Varela</surname><given-names>R</given-names></name><name><surname>Soto-Espinoza</surname><given-names>MI</given-names></name><name><surname>Vargas</surname><given-names>R</given-names></name><name><surname>Quinones</surname><given-names>L</given-names></name><name><surname>Del Campo</surname><given-names>A</given-names></name></person-group><article-title>Influence of BDNF Genetic Polymorphisms in the pathophysiology of aging-related diseases</article-title><source>Aging Dis</source><year>2020</year><volume>11</volume><issue>6</issue><fpage>1513</fpage><lpage>1526</lpage><pub-id pub-id-type="pmid">33269104</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Urbina-Varela R, Soto-Espinoza MI, Vargas R, Quinones L, Del Campo A (2020) Influence of BDNF Genetic Polymorphisms in the pathophysiology of aging-related diseases. Aging Dis 11(6):1513&#x02013;1526<pub-id pub-id-type="pmid">33269104</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>HS</given-names></name><name><surname>Choi</surname><given-names>YJ</given-names></name><name><surname>Han</surname><given-names>HY</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>KS</given-names></name><name><surname>Lim</surname><given-names>SH</given-names></name><name><surname>Heo</surname><given-names>DJ</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name></person-group><article-title>Serum and aqueous humor adiponectin levels correlate with diabetic retinopathy development and progression</article-title><source>PLoS ONE</source><year>2021</year><volume>16</volume><issue>11</issue><fpage>e0259683</fpage><pub-id pub-id-type="pmid">34780524</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Yang HS, Choi YJ, Han HY, Kim HS, Park SH, Lee KS, Lim SH, Heo DJ, Choi S (2021) Serum and aqueous humor adiponectin levels correlate with diabetic retinopathy development and progression. PLoS ONE 16(11):e0259683<pub-id pub-id-type="pmid">34780524</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><mixed-citation publication-type="other">Liu C, Qin L, Ding J, Zhou L, Gao C, Zhang T, Guo M, Huang W, Jiang Z, Long Y et al (2019) Group 2 Innate Lymphoid Cells Participate in Renal Fibrosis in Diabetic Kidney Disease Partly via TGF-beta1 Signal Pathway. J Diabetes Res 2019:8512028</mixed-citation></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>KC</given-names></name><name><surname>Liu</surname><given-names>CC</given-names></name><name><surname>Wu</surname><given-names>JY</given-names></name><name><surname>Ho</surname><given-names>CN</given-names></name><name><surname>Lin</surname><given-names>MC</given-names></name><name><surname>Hsing</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>IW</given-names></name></person-group><article-title>Association between the neutrophil-to-lymphocyte ratio and cognitive impairment: a meta-analysis of observational studies</article-title><source>Front Endocrinol (Lausanne)</source><year>2023</year><volume>14</volume><fpage>1265637</fpage><pub-id pub-id-type="pmid">38089627</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Hung KC, Liu CC, Wu JY, Ho CN, Lin MC, Hsing CH, Chen IW (2023) Association between the neutrophil-to-lymphocyte ratio and cognitive impairment: a meta-analysis of observational studies. Front Endocrinol (Lausanne) 14:1265637<pub-id pub-id-type="pmid">38089627</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Nuthikattu</surname><given-names>S</given-names></name><name><surname>Milenkovic</surname><given-names>D</given-names></name><name><surname>Norman</surname><given-names>JE</given-names></name><name><surname>Villablanca</surname><given-names>AC</given-names></name></person-group><article-title>Single nuclei transcriptomics in diabetic mice reveals altered brain hippocampal endothelial cell function, permeability, and behavior</article-title><source>Biochim Biophys Acta Mol Basis Dis</source><year>2024</year><volume>1870</volume><issue>2</issue><fpage>166970</fpage><pub-id pub-id-type="pmid">38036105</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Nuthikattu S, Milenkovic D, Norman JE, Villablanca AC (2024) Single nuclei transcriptomics in diabetic mice reveals altered brain hippocampal endothelial cell function, permeability, and behavior. Biochim Biophys Acta Mol Basis Dis 1870(2):166970<pub-id pub-id-type="pmid">38036105</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Si</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Pang</surname><given-names>D</given-names></name><name><surname>Jiang</surname><given-names>P</given-names></name></person-group><article-title>Exosomes in brain diseases: Pathogenesis and therapeutic targets</article-title><source>MedComm (2020)</source><year>2023</year><volume>4</volume><issue>3</issue><fpage>e287</fpage><pub-id pub-id-type="pmid">37313330</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Si Q, Wu L, Pang D, Jiang P (2023) Exosomes in brain diseases: Pathogenesis and therapeutic targets. MedComm (2020) 4(3):e287<pub-id pub-id-type="pmid">37313330</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Mone</surname><given-names>P</given-names></name><name><surname>Martinelli</surname><given-names>G</given-names></name><name><surname>Lucariello</surname><given-names>A</given-names></name><name><surname>Leo</surname><given-names>AL</given-names></name><name><surname>Marro</surname><given-names>A</given-names></name><name><surname>De Gennaro</surname><given-names>S</given-names></name><name><surname>Marzocco</surname><given-names>S</given-names></name><name><surname>Moriello</surname><given-names>D</given-names></name><name><surname>Frullone</surname><given-names>S</given-names></name><name><surname>Cobellis</surname><given-names>L</given-names></name><etal/></person-group><article-title>Extended-release metformin improves cognitive impairment in frail older women with hypertension and diabetes: preliminary results from the LEOPARDESS Study</article-title><source>Cardiovasc Diabetol</source><year>2023</year><volume>22</volume><issue>1</issue><fpage>94</fpage><pub-id pub-id-type="pmid">37085892</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Mone P, Martinelli G, Lucariello A, Leo AL, Marro A, De Gennaro S, Marzocco S, Moriello D, Frullone S, Cobellis L et al (2023) Extended-release metformin improves cognitive impairment in frail older women with hypertension and diabetes: preliminary results from the LEOPARDESS Study. Cardiovasc Diabetol 22(1):94<pub-id pub-id-type="pmid">37085892</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Mone</surname><given-names>P</given-names></name><name><surname>Lombardi</surname><given-names>A</given-names></name><name><surname>Gambardella</surname><given-names>J</given-names></name><name><surname>Pansini</surname><given-names>A</given-names></name><name><surname>Macina</surname><given-names>G</given-names></name><name><surname>Morgante</surname><given-names>M</given-names></name><name><surname>Frullone</surname><given-names>S</given-names></name><name><surname>Santulli</surname><given-names>G</given-names></name></person-group><article-title>Empagliflozin improves cognitive impairment in Frail older adults with type 2 diabetes and heart failure with preserved ejection fraction</article-title><source>Diabetes Care</source><year>2022</year><volume>45</volume><issue>5</issue><fpage>1247</fpage><lpage>1251</lpage><pub-id pub-id-type="pmid">35287171</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Mone P, Lombardi A, Gambardella J, Pansini A, Macina G, Morgante M, Frullone S, Santulli G (2022) Empagliflozin improves cognitive impairment in Frail older adults with type 2 diabetes and heart failure with preserved ejection fraction. Diabetes Care 45(5):1247&#x02013;1251<pub-id pub-id-type="pmid">35287171</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Hay</surname><given-names>M</given-names></name><name><surname>Polt</surname><given-names>R</given-names></name><name><surname>Heien</surname><given-names>ML</given-names></name><name><surname>Vanderah</surname><given-names>TW</given-names></name><name><surname>Largent-Milnes</surname><given-names>TM</given-names></name><name><surname>Rodgers</surname><given-names>K</given-names></name><name><surname>Falk</surname><given-names>T</given-names></name><name><surname>Bartlett</surname><given-names>MJ</given-names></name><name><surname>Doyle</surname><given-names>KP</given-names></name><name><surname>Konhilas</surname><given-names>JP</given-names></name></person-group><article-title>A Novel Angiotensin-(1&#x02013;7) glycosylated mas receptor agonist for treating vascular cognitive impairment and inflammation-related memory dysfunction</article-title><source>J Pharmacol Exp Ther</source><year>2019</year><volume>369</volume><issue>1</issue><fpage>9</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">30709867</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Hay M, Polt R, Heien ML, Vanderah TW, Largent-Milnes TM, Rodgers K, Falk T, Bartlett MJ, Doyle KP, Konhilas JP (2019) A Novel Angiotensin-(1&#x02013;7) glycosylated mas receptor agonist for treating vascular cognitive impairment and inflammation-related memory dysfunction. J Pharmacol Exp Ther 369(1):9&#x02013;25<pub-id pub-id-type="pmid">30709867</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Miao</surname><given-names>Y</given-names></name><name><surname>Ji</surname><given-names>X</given-names></name><name><surname>Bi</surname><given-names>Y</given-names></name></person-group><article-title>Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: a systematic review and network meta-analysis</article-title><source>Diabetes Metab Res Rev</source><year>2023</year><volume>39</volume><issue>7</issue><fpage>e3673</fpage><pub-id pub-id-type="pmid">37302139</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Tian S, Jiang J, Wang J, Zhang Z, Miao Y, Ji X, Bi Y (2023) Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: a systematic review and network meta-analysis. Diabetes Metab Res Rev 39(7):e3673<pub-id pub-id-type="pmid">37302139</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Jende</surname><given-names>JME</given-names></name><name><surname>Mooshage</surname><given-names>C</given-names></name><name><surname>Kender</surname><given-names>Z</given-names></name><name><surname>Kopf</surname><given-names>S</given-names></name><name><surname>Groener</surname><given-names>JB</given-names></name><name><surname>Heiland</surname><given-names>S</given-names></name><name><surname>Juerchott</surname><given-names>A</given-names></name><name><surname>Nawroth</surname><given-names>P</given-names></name><name><surname>Bendszus</surname><given-names>M</given-names></name><name><surname>Kurz</surname><given-names>FT</given-names></name></person-group><article-title>Magnetic resonance neurography reveals Smoking-Associated decrease in sciatic nerve Structural Integrity in Type 2 diabetes</article-title><source>Front Neurosci</source><year>2021</year><volume>15</volume><fpage>811085</fpage><pub-id pub-id-type="pmid">35242003</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Jende JME, Mooshage C, Kender Z, Kopf S, Groener JB, Heiland S, Juerchott A, Nawroth P, Bendszus M, Kurz FT (2021) Magnetic resonance neurography reveals Smoking-Associated decrease in sciatic nerve Structural Integrity in Type 2 diabetes. Front Neurosci 15:811085<pub-id pub-id-type="pmid">35242003</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Yan</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name></person-group><article-title>Identification of independent risk factors for diabetic neuropathy progression in patients with type 2 diabetes mellitus</article-title><source>J Int Med Res</source><year>2021</year><volume>49</volume><issue>9</issue><fpage>3000605211044366</fpage><pub-id pub-id-type="pmid">34559575</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Huang L, Shen X, Huang L, Yan S, Wu P (2021) Identification of independent risk factors for diabetic neuropathy progression in patients with type 2 diabetes mellitus. J Int Med Res 49(9):3000605211044366<pub-id pub-id-type="pmid">34559575</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Lei</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>T</given-names></name><name><surname>Lv</surname><given-names>H</given-names></name></person-group><article-title>Analysis of risk factors of diabetes peripheral neuropathy in type 2 diabetes mellitus and nursing intervention</article-title><source>Exp Ther Med</source><year>2020</year><volume>20</volume><issue>6</issue><fpage>127</fpage><pub-id pub-id-type="pmid">33082859</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Li Z, Lei X, Xu B, Wang S, Gao T, Lv H (2020) Analysis of risk factors of diabetes peripheral neuropathy in type 2 diabetes mellitus and nursing intervention. Exp Ther Med 20(6):127<pub-id pub-id-type="pmid">33082859</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Yeboah</surname><given-names>K</given-names></name><name><surname>Puplampu</surname><given-names>P</given-names></name><name><surname>Boima</surname><given-names>V</given-names></name><name><surname>Antwi</surname><given-names>DA</given-names></name><name><surname>Gyan</surname><given-names>B</given-names></name><name><surname>Amoah</surname><given-names>AGB</given-names></name></person-group><article-title>Peripheral sensory neuropathy in type 2 diabetes patients: a case control study in Accra, Ghana</article-title><source>J Clin Transl Endocrinol</source><year>2016</year><volume>5</volume><fpage>26</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">29067231</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Yeboah K, Puplampu P, Boima V, Antwi DA, Gyan B, Amoah AGB (2016) Peripheral sensory neuropathy in type 2 diabetes patients: a case control study in Accra, Ghana. J Clin Transl Endocrinol 5:26&#x02013;31<pub-id pub-id-type="pmid">29067231</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>